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NOTE OF TRANSMITTAL 
This study of the potential economic and social benefits of the space processing of three biologi-
cal substances was performed for the Lyndon B. Johnson Space Center, National Aeronautics and Space 
Administration, under Contract NAS-9-l5338. The NASA Technical Officer for this study was Mr. Herbert 
Greider . 
The ECON study team consisted of Ms. Celia Drumheller, Mr. Keith Lietzke, Mr. B. P. Miller, Mr. 
Jay Perrine and Dr. Mark Thompson. Ms. Drumheller and Mr. Lietzke performed the study of Beta cells, 
Mr. Perrine performed the study of lymphocytes and urokinase-producing cells and Dr. Thompson examined 
the methodologies used for the evaluation of the econo~ic and social impacts of biomedical research. 
Mr. B. P. Miller was Project Manager for this study. 
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OBJECTIVES OF STUDY 
The objectives of this study are to evaluate and select methodologies for use in estimating the 
potential economic and social benefits of applications of the NASA space bioprocessing program. The 
selected methodologies are then to be usej to estimate the potential benefits that could result from 
the successful research and clinical application of three candidate space bioprocessing substances. 
The central questions to be answered in this study are: 
1. What are the accepted methodologies for the evaluation of the benefits 
of medical research? 
2. What are the estimated potential benef{ts that could result from a 
successful research and clinical application program for specified 
candidate substances for space bioprocessing? 
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OBJECTIVES OF STUDY 
SURVEY METHODOLOGIES USED TO ESTIMATE BENEFITS OF MEDICAL RESEARCH . 
RECOMMEND ACCEPTABLE METHODOLOGIES FOR THE EVALUATION OF THE ECONOMIC 
AND SOr:AL BENEFITS OF CANDIDATE SUBSTANCES FOR NASA SPACE BIOPROCESSING 
PROGRAM. 
ESTIMATE THE POTENTIAL BENEFITS OF SUCCESSFUL RESEARCH AND CLINICAL 
APPLICATION OF THREE SUBSTANCES THAT ARE CANDIDATES FOR SPACE BIO-
PROCESSING. THE THREE CANDIDATE SUBSTANCES ARE: 
+ SEPARATION AND CLASSIFICATION OF LYMPHOCYTE SUBGROUPS 
+ SEPARATION OF UROKINASE-PRODUCING CELLS 
+ SEPARATION OF BETA CELLS. 
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CANIJIDATE SUBSTANCES AND APPLICATIONS STUDIED 
The purpose of the work described in this report is to provide a rational analytical bas
is for the 
evaluatiol~ of the potential benefits of the processing of biological materials in space. 
These quanti-
tative evaluations could then be used by decision makers, in conjunction with other information, as a 
basis for the selection of candidate projects. In the work performed to date, a preliminary evaluation 
has been made of the potential benefits of three candidate space processed biological ma
terials. The 
three materials investigated are human lymphocytes, urokinase and Beta cells< In the cas
e of human 
lymphocytes, electrophoresis is to be used to separate and classifY lymphocyte subgroups 
in order to 
improve the matching of donors and recipients for kidney transplantation. It is believed
 that lympho-
cytes play an important role in immune functions, and that the results of the proposed re
search, if 
successful, could lead to improved kidney transplant acceptance. Urokinase is a drug wh
ich appears to 
be able to dissolve blood clots, and may be useful in the treatment of thromboembolic dis
eases. Uro-
kinase can either be extracted from human urine or from kidney cells. Urokinase produced
 from human 
urine is not used in the United States because of purity problems with fever-producing p
recursors which 
are difficult to remove from the urine. The alternative technique for the production of 
urokinase is 
to separate urokinase-producing cells from all other kidney cells. It has been theorized
 that using 
electrophoretic separation in space, kidney cells could be separated with respect to cell
 function, and 
returned to earth in a viable condition. Then, the urokinase-producing cells would be pr
opagated in 
earth-based facilities. 
Beta cells found in the human pancreas could provide a highly effective means for the tre
atment of 
juvenile-onset diabetes. As in the case of lymphocytes and urOkinase, it is believed that electrophoretic 
separation in space could be used to extract Beta cells which could then be injected into a diabetic 
patient. If successfully accomplished, the use of Beta cells could eliminate many of the
 complications 
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SUBSTAfICE SPACE PROCESS MECHANISM 
BETA CELLS SEPARATE BETA CELLS FROM ELECTROPHORESIS 
OTHER PANCREATIC CELLS 
LYMPHOCYTES SEPARATE AND CLASSIFY ELECTROPHORESIS 
LYMPHOCYTE SUBGROUPS 
UROKINASE SEPARATE UROKINASE- ELECTROPHORESIS 
PRODUCING CELLS FROM 
OTHER KIDNEY CELLS 
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CLINICAL APPLICATION 
INSULIN-DEPENDENT DIABETICS 
KIDNEY TRANSPLANTS IN 
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CLI N I CAL IMPACT 
REDUCE INCIDENCE AND 
SEVERITY OF COMPLI-
CATIONS OF DIABETES 
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STUDY APPROACH 
The approach used in this study is delineated in the opposite chart. 
An extensive review of the literature of the economics of medical research was performed 
to iden-
tify the techniques used for the estimation of benefits of medical research. This study 
of methodolo-
gies identified the fact that it is necessary to consider both the economic and social b
enefits of 
medical research. The economic (or direct benefit) results from the reduced cost of a disease treatment 
which would yield an equal or greater productive life expectancy when comp~(cd to presen
t treatments of 
the same disease. The social (or indirect benefit) stems from the possible extension of life and in-
creased productivity from improved health resulting from the new disease treatment. Usin
g available 
statistics on the current methods of treatment and expert estimates on the new methods of
 treatment, 
the benefits of the proposed research are calculated as the differences between the costs
 and produc-
tive life expectancies associated with existing treatment systems, and similar character
istics associated 
with the new treatment systems that could result from the processing of biological mater
ials in space. 
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STUDY APPROACH 
• REVIEW LITERATURE ON f1ETHODOLOGIES FOR ESTIMATION OF ECONOMIC AND SOCIAL BENEFI7S OF MEDICAL RESEARCH 
II SELECT METHODOLOGIES FOR EVALUATION OF ECONOMIC AND SOCIAL BENEFITS THAT 
ARE WIDELY USED AND GENERALLY ACCEPTED 
• SELECT CLINICAL APPLICATIONS FOR THE THREE CANDIDATE SUBSTANCES FOR SPACE BIOPROCESSING 
• OBTAIN MORTALITY, MORBIDITY AND COST STATISTICS FOR CURRENT TREATMENT OF SELECTED CLINICAL APPLICATIONS 
• OBTAIN ESTIMATES OF IMPACT OF CANDIDATE SUBSTANCES ON MORBIDITY, MORTALITY AND COST OF TREATMENT 
• ESTIMATE THE POTENTIAL ECONOMIC AND SOCIAL BENEFITS OF THE THREE CANDIDATE SUBSTANCES USING THE SELECTED METHODOLOGIES 
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SUI~I~ARY OF RESULTS 
This study has shown that several methodologies are used in the fields of health care eco
nomics, 
insurance and systems analysis to evaluate the benefits of improved disease treatment sys
tems. ECON 
has selected a transitional probability (Markovian) methodology to model the disease treatment and to 
provide insight into the impact of new treatment system on morbidity, mortality, as well 
as the duration 
and cost of treatment. Using the model of the disease treatment system, the results are 
quantified as 
changes in the cost of treatment of the disease and its complications and as increased in
come as a result 
of an extended productive lifetime. 
The techniques used in this analysis (transitional probabi1ity modeling and present value of future 
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SUMMARY OF RESULTS 
STUDY HAS IDENTIFIED ACCEPTABILITY OF TRANSITIONAL PROBABILITY METHODOLOGY AND VALUE 
OF HUMAN CAPITAL APPROACH TO ESTIMATION OF ECONOMIC AND SOCIAL BENEFITS OF IMPROVED 
DISEASE TREATMENT 





END STAGE RENAL DISEASE (LYMPHOCYTE SUBGROUP SEPARATION) 
PULMONARY EMBOLISMS (SEPARATION OF UROKINASE PRODUCING CELLS) 
+ HUMAN DIABETES (SEPARATION OF BETA CELLS) 
ESTIMATED THE POTENTIAL ECONOMIC AND SOCIAL BENEFITS OF SPACE BIOPROCESSING IN EACH 
OF THE ABOVE DISEASE TREATMENTS 
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SUMMARY OF BENEFITS 
This figure summarizes the quantified economic and social benefits for the three candidate sub-
stances and clinical applications studied. For the purpose of this study, it was assumed that the new 
treatment systems would be available for initial use in 1985. It should be noted that the total bene-
fits are given for the lifetime of the initial patient population that begins treatment in 1985, and 
that additional benefits could be realized as the new treatment systems are used for additional patients 
in each successive year. 
Annual benefits for each year of treatment from disease onset to patient death have been discounted 
by 6 percent per year to the initial year to reflect the time value of money. Aggregate benefits are 
expressed in 1985 dollars since this is the assumed first year of operation. A 6 percent inflation 
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SUMt1ARY OF BENEFITS 
(ALL DOLLAR VALUES ARE 1985$ AT 6% DISCOUNT AND H'FLATION RATES) 
HUMBER Of BENmT PER YEARS OF LJ FE AVERAGE PER AYERAGE PER PERSON ESTIMATED TOTAL 
CANDIDATE PATIENTS PERsop,r FROM PER PERSON EX- PERSOIi PRIVATE PRIVATE BENEFIT FROM BE!jEFIT FOR 
SUBSTANCE PER YEAR n~f OF TENDED BY THE BENEFIT FRDM EXTENDED LIFE 11 FETIME OF BECOMING • SPACE-BASED REDUCED TREAT- IIIITIAL TREATMENT 
AFFLICTED otSEASt: ONSET EttOEAV<.R HENT CDSTS (EARllItlGS) PDPULATIOH 
l YMPHDCYlE 10,000 $124,222 3.39 111,667 $22,670 \ l,2DD,DOD,DDD 
SEPARATIOII 
uROKJI!ASE 750,000 $ 4,052 1.56 S - B5 $ 4,137 $ 3.000,000,000 
BETA CELLS 1.240,ODD 
... $ 2,,9DO 5.2 $l1,04D ***:r. $12,B60 129,600,DOD,DDO 




ASSUMES BETA CELL TRANSPLANT. 
THIS IS THE NUMBER OF DIABETICS WHD COULD CONSTITUTE THE TREATl1EHT POPULATIOII III THE FIRST YEAR. THE POPULATIDH IN 
SUCCESSIVE YEARS WOULD BE INCREASED BY THE IHCREM[rnAL IIUMBER OF NEW JUYErfILE-OIISET DIABETICS DIAGNOSED III THAT YEAR. 







ARE OTHER DISEASE 
TREATHEUTS POTENTIALLY 
IMPACTED BY THIS SPACE~ 
PROCESSIHG SPECIMEN 
YES, OTHER TRAIISPLANTS 
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RECOMMENDATIONS 
The results of this study conclusively demonstrate that it is possible to use analytical techniques 
to quantify the potential economic and social benefits of new treatment systems that could be developed 
as a result of successful space bioprocessing experimentation. The specific benefit estimates are highly 
sensitive to the cost, morbidity and mortality input data used in the models. For this reason, it is 
recommended that the benefit estimates be considered to be preliminary until further work can be done to 
improve the quality of the input data. 
Several other substances are also candidates for space bioprocessing experiments. It is recommended 
that this benefit study be continued to examine the potential benefits of additional candidate substances, 
thus providing a basis for comparing experiments that could compete for limited resources. 
As the reader of this report will note, this is not a benefit/cost study. The costs of the 
space research, ground research and clinical trials leading to an approved pharmaceutical product have 
not been considered in this study. Moreover, the benefits assume that the space research and subsequent 
clinical trials will be fully successful. In order to rate the candidate substances, it is recommended 
that the additional dimensions of cost and probable outcomes of the research and development programs be 
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RECOMMENDATIONS 
CONTINUE STUDIES TO REFINE COSTS AND rROBABILITIES OF SUCCESS OF THE CANDIDATE SPACE 
BIOPROCESSING PROJECTS AND OTHER COMPETITIVE METHODS OF ACHIEVING THE SAME TREATMENT 
OBJECTIVES 
MODEL DISEASE TREATMENTS AND ESTIMATE BENEFITS FOR OTHER SEPARATION CANDIDATES AND 
CLINICAL APPLICATIONS SUCH AS: 









GrllNULOCYTES - TRANSFUSION FOLLOWING CHEMOTHERAPY AND/OR IRRADIATION FOR 
ACUTE MYELOBLASTIC LEUKEMIA 
MEGAKARYOCYTES - TRANSFUSION FOLLOWING CHEMOTHERAPY AND/OR IRRADIATION 
TREATMENT FOR TUMOR CANCERS 
PEPTIDE HORMONES - POST STEROID THERAPY 
13 
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OBJECTIVES: CONTRACT NAS-9-l533C 
In a previous study for NASA Headquarters, ECON developed and applied a methodology for the 
evaluation of the potential benefits of space-based research in lymphocyte subgroup separation, and 
the separation of urokinase-producing cells.' 
The present study has three objectives. The first is to evaluate the acceptance of the methodology 
used for the estimation of economic benefits in our earlier study within the community of economists 
and public policy analysts who work on the evaluation of biomedical research. A second objective is to 
reassess the economic benefit5 and to evaluate the social benefits of lymphocyte subgroup separation 
and the separation of urokinase-producing cells. The third objective is to evaluate the economic and 
social benefits of the separation of Beta cells . 
----I 
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OBJECTIVES: CONTRACT NAS-9-15338 
1, EVALUATE THE ACCEPTABILITY WITHIN THE MEDICAL RESEARCH ECONOMICS COMMUNITY 
OF THE METHODOLOGY FOR BENEFIT EVALUATION PREVIOUSLY DEVELOPED AND APPLIED 
BY ECON TO SPACE BIOPROCESSING PROBLEMS UNDER CONTRACT TO NASA HEADQUARTERS. 
2. REESTIMATE THE ECONOMIC BENEFITS AND QUANTIFY THE SOCIAL BENEFITS IN THE 
TWO AREAS OF SPACE BIOPROCESSING WHERE ECON HAS PREVIOUSLY ESTIMATED THE 
ECONOt1IC BENEFITS. THE TWO AREAS ARE LYMPHOCYTE SUBGROUP SEPARATION AND 
CLASSIFICATION, AND THE SEPARATION OF UROKINASE-PRODUCTION CELLS. 
3. ESTIMATE THE ECONOMIC AND SOCIAL BENEFITS FOR SEPARATION OF BETA CELLS IN 
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BACKGROUND 
In our previously referenced study for NASA Headquarters', two promlslng candidate substances 
for space bioprocessing were selected for benefit evaluation. These two substances were lymphocytes 
and urokinase. In the case of lymphocytes, ground-based research has led to the classification of 
two subgroups, and the objective of the space-based research is to further separate and extend the 
classification process within the two presently identified subgroups. At the present time, using 
ground-based techniques, urokinase-producing cells cannot be separated from other kidney cells. In 
both instances, electrophoretic separation in space has been proposed as the mechanism to effect 
separation. The clinical application selected for study in connection with lymphocyte subgroup 
classificntion, is the matching of donors and recipients for kidney transplantation; while the 
application selected for urokinase is the reduction of blood clots associated with pulmonary embolisms. 
While other possible applications exist for these two substances, these two applications represent 
areas where immediate progress could be made if the space-based research is successful . 
This preliminary study concluded that very large economic benefits could result from successful 
lymphocyte subgroup separation. During this earlier study, it was also determined that it is possible 
that urokinase production costs could be reduced as a result of the successful separation of urokinase-
producing cells, thus leading to increased availability and widespread use of urokinase in the treat-
ment of thromboembolic diseases. This, in turn, could lead to a reduction in the number of deaths 
from pulmonary embolisms, and could possibly reduce the need for some surgical procedures and thus 
reduce the length of hospital stay. 
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• PREVIOUS STUDY OF LYMPHOCYTE SUBGROUP SEPARATION AND SEPARATION OF UROKINASE-
PRODUCING CELLS USED TRANSITIONAL PROBABILITY TECHNIQUES TO ESTIMATE ECONOf1IC 
BENEFITS 
. 
SUOSTAI1CE LYMPHOCYTES UROKINASE 
SPACE PROCeSS SEPARATE AND CLASSIFY SUBGROUPS SEPARATE AND CONCENTRATE 
UROKINASE-PRODUCING CELLS 
MECHANISM ELECTROPHDRISIS F.LECTROPHORISIS 
CLINICAL APPLICATION KIDNEY TRANSPLANTATION TH~OMBOEMBOLIC DISEASES 
CLINICAL IMPACT IMPROVE TRANSPLANT ACCEPTANCE LYSE BLOOD CLOTS 
- - -- ---
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THE NEED FOR QUANTIFIED ESTIMATES OF BENEFITS 
The common starting point for analysts of biomedical research is the need to quantify estimates 
of benefit. This need is apparent in decision making. In annual budget processes, research projects 
compete against each other and ,:lith other social priorities for 1 imited resources. Whenever one project 
is funded in preference to another of equal cost, it is implicitly rated higher on the scale of antici-
pated benefits. To date, that scale has primarily reflected scientific merit, although recent years 
have seen efforts to bring encompassing societal priorities to bear. 
As conceptual difficulties, data deficiencies, and individual resistance have hampered explicit 
quantification of the rationale behind funding decisions, ~hey continue to be made on an ad hoc basis. 
For so long as the obstacles to quantification endure, opportunities for inconsistency persist. 
Quantifying the expected benefits forces decision makers to adopt a consistent comprehensible scale (1) 
for explaining and justifying their actions, (2) for enabling systematic adherence to relevant priorities 
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THE NEED FOR QUANTIFIED ESTIMATES OF BENEFITS 
• COMPETITION FOR LIMITED RESOURCES 
• DECISIONS BASED UPON SCIENTIFIC MERIT AND SOCIETAL PRIORITES 
• ENCOURAGES DECISION MAKERS TO ADOPT A CONSISTENT AND UNDERSTANDABLE 
SCALE FOR 
+ EXPLAINING ACTIONS 
+ MAINTAINING ADHERENCE TO PRIORITIES 
+ RELATING RESOURCE COt~MITMENTS TO EXPECTED RESULTS 
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DEFINITION OF ECONOMIC AND SOCIAL BENEFITS 
Two classes of benefits must be considered when the benefits of a proposed new method of disease 
treatment are to be evaluated. For the purpose of this study, these two classes of benefits are 
considered to be the economic (or direct) benefits and social (or indirect) benefits. The economic 
benefits are defined as those benefits that occur in the private and public sector from the changes 
in the cost of treatment of the disease and its complications. Social benefits are defined as those 
benefits that result from decreases in mortality and/or morbidity as a result of the r.ew treatment 
process. For example, prior to the use of penicillin, many bacterial infections required hospitiliza-
tion and long periods of convalescence. With the use of penicillin, an economic benefit results as the 
cost of treatment of bacterial infection has been decreased. Further, a social benefit also results as 
the use of penicillin has reduced the incidence of death and periods of disability from bacterial 
infection. 
The purpOSe of a benefit evaluation study is to express these benefits in measurable quantities 
such as dollar~ nnd years of life extension. 
22 
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DEFINITION OF ECONOMIC AND SOCIAL BENEFITS 
• TWO BENEFIT COMPONENTS 
+ ECONOMIC - COST OF DISEASE TREATMENT 
+ SOCIAL - DECREASED MORTALITY AND/OR INCREASED PRODUCTIVITY 
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SOCIAL BENEFITS 
An improved state of health is a social benefit which can be measured in several ways. 
The 
number of persons who avoid a premature death can be counted and a value placed on thei
r lives. 
Death can be postponed for some period of time which can be measured. Regardless of wh
ether life is 
extended there is often increased productivity from improved health, that is, people wh
o might 
otherwise be debilitated could return to work. Most of these improvements can then be 
quant~fied in 
dollars or some scalar quantity such as average number of years of life extension. Whe
n these benefits 
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SOCIAL BENEFITS 
• DECREASED MORTALITY 
• 
• 
+ AVOID DEATH FROM SERIOUS ILLNESS 
+ POSTPONE DEATH FOR N NUflBER OF YEARS IN SEMIHEALTHY 
STATE 
INCREASED PRODUCTIVITY 
+ IMPROVED HEALTH 
+ SHORTENED MEDICAL TREATMENT 
CONVERT ABOVE TO SCALAR QUANTITI ES 
25 
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KEY QUESTI ON 
The key question to be addressed in the evaluation of social benefits is: 
of extending the life of a person who is afflicted with some specific disease? 
rephrased as: What is the benefit of extending the average life expectancy of 
afflicted with the same disease? 
26 
What is the benefit 
This question can be 
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VALUING HUr~AN LIVES 
The concept of placing an economic value on reductions in mortality and morbidity is common 
to several professions. The techniques used in these professions were revievled in order to select 
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VALUING Hur~AN LIVES 
INVESTIGATED TECHNIQUES USED TO VALUE HUnAN LIVES FROM 
SEVERAL PROFESSIONAL PERSPECTIVES 
• LAW 
• INSURANCE 
• ECONOMICS, ESPECIALLY HEALTH ECONOMICS 
• SYSTEMS ANALYSIS OF MEDICAL RESEARCH BENEFITS 
29 
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INSURANCE INDUSTRY APPROACH 
The insurance industry was one of the first to place a value on a human life in order to sell 
insurance on the value obtained. The approach utilized is to sum all future earnings from the present 
until age 65, first subtracting costs for one's own consumption, and then discounting that amount to 
the present using a risk-free interest rate (about 4 percent). The concept is that a person, particularly 
a family breadwinner, should insure his life for an amount equal to the capitalized value obtained so 
that in the event of his death the family would obtain an income equal to that of the deceased if he 
had survived. This technique is called the capitalized human value method, or human capital technique. 
30 
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INSURANCE INDUSTRY APPROACH 
SUM ALL FUTURE EARNINGS TO AGE 65 (OR 62), SUBTRACT ONE'S OWN 
CONSUMPTION, AND THEN OBTAIN PRESENT VALUE OF THE NET USING A 
SUITABLE RISK-FREE INTEREST RATE. 
(ONE SHOULD THEN OBTAIN INSURANCE EQUAL TO THIS AMOUNT TO 
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LIFE VALUES FROM LEGAL JUDGMENTS 
The courts have long been called upon to determine the value of a human who has been kil
led in a 
manner where fault can be proven, such as in a plane crash or auto accident. After the 
determination 
of guilt by legal methods, the decision has to be made on a pecuniary value in the wrong
ful death case. 
The award is generally made after expert testimony by an actuary or economist who in som
e manner calcu-
lates the present value (discounted) of expected future earnings and, depending on state laws, adds 
additional sums for such family losses as training of children. These awards are entire
ly dependent 
on the exact situation of the person at the time of death (age, income, family size, dependents, age 
of dependents, etc.). 
32 
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LIFE VALUES FROM LEGAL JUDGMENTS 
IN WRONGFUL DEATH CASES THE AWARD IS USUALLY DETERMINED BY: 
• EXPERT TESTIMONY ON THE PRESENT VALUE OF EXPECTED FUTURE 
EARNINGS (FOR A CHILD. THE PROBABLE EARNINGS MINUS SUPPORT 
COSTS TO RAISE CHILD TO ADULTHOOO) 
• PECUNIARY LOSS OF PRESENT AND PROBABLE FUTURE BENEFITS 
• 
+ TRAINING. GUIDANCE AND ADVICE (ESPECIALLY OF CHILDREN) 
+ SOCIETY AND COMPANIONSHIP 
TOTAL AWARD QUITE DEPENDENT ON CONDITIONS AT TIME OF DEATH (INCOME. AGE. DEPENDENTS. ETC . ) 
33 
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ECONmlICS AND SYSTEMS ANALYSIS APPROACHES 
Medical economics and systems analysis studies have utiliz2d the four techniques listed on the 
opposite page. These techniques will be discussed on the following pages. 
34 
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ECONOMICS AND SYSTEMS ANALYSIS APPROACHES 
IN GOVERNMENT BENEFIT-COST AND MEOICAL RESEARCH FUNDING 
STUDIES, FOUR TECHNIQUES HAVE BEEN EMPLOYED: 
1. HUMAN CAPITAL TECHNIQUE 
2. IMPLICIT VALUE TECHNIQUE 
3 . LIFE-VALUE TECHNIQUE 
4. WILLINGNESS-TO-PAY TECHNIQUE 
35 
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HUMAN CAPITAL TECHNIQUE 
The human capital technique, in which future earnings are discounted to obtain present v
alues, is 
widely utilized. Tables are generated from government-supplied employment and income st
atistics so that 
all members of society are represented. This technique has by far the widest utilizatio
n. Medical 
studies generally make use of tables generated by Dorothy P. Rice, who is now the direct
or of the 
National Center for Health Statistics. The criticisms against the use of this technique
 are that women, 
the elderly and minorities are unfairly valued and that income, in general, is no indica
tor of worth. 
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HUMAN CAPITAL TECHNIQUE 
PRESENT VALUE OF FUTURE EARNINGS, SOMETIMES 
SUBTRACTING PERSONAL CONSUMPTION 
• MOST WIDELY USED TECHNIQUE 
+ MANY MEDICAL STUDIES UTrLIZE TABLES 
~. --'._- -- -'" '-'--~--------'----'-'-
AND TECHNIQUE ESTABLISHED BY D. P. RICE 
• 
• 
DATA WIDELY AVAILABLE 
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IMPLICIT VALUE TECHNIQUE 
This technique obtains the value of human lives implicitly. This circular argument assumes that 
if each life saved by a new road intersection project was valued at $15,000, then the value of human 
lives must, in fact be $15,000. If an ejector seat for a military plane costs the equivalent of 
$1 million per expected life saved, do we use that value or the value implicit in the highway project? 
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IMPLICIT VALUE TECHNIQUE 
OBTAIN VALUE OF HUMAN LIVES IMPLICIT IN 
PREVIOUS GOVERNMENT PROJECTS 
• CIRCULAR ARGUMENT 
• WHICH PROJECTS? 
+ VALUES MAY RANGE FROM 10,000 
TO 1,000,000 
• ARE PAST OECISIONS GUIDELINES FOR 
PRESENT EFFORTS? 
39 
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LIFE-VALUE TECHNIQUE 
The life-value technique utilizes life insurance purchases and/or court awards as the basis for 
valuing human life. If a person purchases only $15,000 of insurance, does that establish his/her life 
value? In like manner, which court cases should be chosen, the ones where the jury was liberal or very 
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LIFE-VALUE TECHNIQUE 
UT I LlZE INSURANCE PUPCHASE OR COURT AHAPD DEC! SJOflS 
r·) PIISIS FOR VALUE OF HUWHI lIFE 
• HlSURANCE PURCHASED IS NOT All IUDICATION OF SELF-tlORTH 
• ACCEPTANCE OF S100,000 FOP. AN ASSIGmmn ,lITH OIIE CHAriCE 
IN FIVE OF DEATH CAWIOT HEAN ACCEPWICE OF CERTAI!I DEATH 
FOR $500,001): 
" HHICH COURT CASES SHOULD BE UTILIZED? 
• LITTLE USE i~MJE fJF THIS TECH/HOUE 
41 









.. ':1i/4- ~ , 





"' ........... ::-,,~:~""";:.;.;..~~~~,;;.J-.~-:.:_"'.~"';,~::-:=.~c-,-"~:~,="'~, ="'" .,' ~':,S:-~~ 





HI LLI NGNESS- TO-PAY TECHNIQUE 
Considerable interest is given this approach
 in economic literature. The drawback is th
at many 
surveys need to be conducted to establ ish th
is as an acceptabl e technique, a procedure t
oo c'lstly for 
most research projects needing this information. The one
 survey conducted produced values closely 
resembling the human capital approach. This
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CONDUCT A SURVEY TO DETERl1HIE HHAT PRICE PEOPLE HOULD PAY TO CONDUCT RESEARCH TO ELH~HlATE A SPECIFIC DISEASE AND EXTRAPOLATE LIFE VALUES 
• ANSylERS FR0I1 ONE SURVEY RESEt·1BLED HUf1AN CAPITAL APPROACH 
• TOO LITTLE EI·1PIRICAL EVIDENCE AVAILABLE TO SUPPORT THE TECHNIQUE 
• NO INCENTIVE (VI PART OF THE RESPONDENT TO PROVIDE TRUE PREFERE:ICES 
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VALUE OF HUMAN CAPITAL 
This chart illustrates typical human capital curves as developed over a decade ago by Dorothy P. 
Rice and recently updated to reflect current experience'. The value obtained from these curves for 
any particular year of an average person's life represents the discounted value. Thus, if that sum 
were invested in an interest-bearing savings account, withdrawals equal to the average salary could be 
made for the years which the deceased would have lived. The total money thus withdrawn from the 
account would yield far more than the amount deposited (the amount of the value at the age on the curve). 
-, The Economic Cost of Illness Revisited. Barbara S. Cooper and Dorothy P. Rice. Social Security 






































VALUE OF HUMAN CAPITAL 
- - ._ .. -.. -..... -- ... - ~ .. ~- ._._--
WM - white I'T'IQlei 
Wf - wh ite rernolH 
AOM - 011 other ",ole, 
AOF - all other """,1 .. 
WF 
-:1\\ 
S 10 15 20 2S 30 35 40 45. SO 55 60 65 70 75 80 B5 90 
Age (yeon) 
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SAMPLE CALCULATION FOR VALUE OF HUMAN CAPITAL 
In order to better understand the present value of future earnings, this simplified example is 
provided. The example assumes a white male. age 40 is earning $10,000 per year until age 65 and then 
his value would be $1,000 per year keeping house. We assume here that he suddenly loses his life and 
we want to plot his potential future earnings if he had not died. The cumulative and the discounted 
value of those earnings is shown. The discounted value assumes a six percent discount rate and the 
earnings are discounted back to age 40. The cumulative discounted value at the end of the curve 
(age 90) would be one point (at age 40 - white male) on the discounted life earnings curve if actual 
income figures had been used in this example. 
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SAMPLE CALCULATIONS FOR VALUE OF HUMAN CAPITAL 
ASSUMED: WHITE MALE, AGED 40, INCOME $lO,OQO/YR * 
UNTIL AGE 65, THEN $lOOOjYR (HOUSEKE~;iNG VALUE) 
CONSTANT YEAR $'5 
DISCOUNTED AT 6% 
50 60 70 80 90 
Note that the incomes used in this salnple calaculatio~ 
are illustrative. For this reason, the numerical results 
obtained differ sllqhtly from the actual figures In the 




ONE ENTRY ON 
THE VALUE OF 
A HUMAN CAP !TAL 
CURVE 
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r~ODIFI ED VALUE OF HUMAN CAPITAL 
ECON has selected the Value of Human Capital technique for the purpose of quantifying so
cial 
benefits. This choice was made based on the wide acceptance by the medical economic com
munity 
and the availability of well-documented data to produce such tables and life-value curve
s. To 
modify the curves we have obtained average-earnings data from the Department of Labor, an
d we 
have made minor modifications to remove some sex and race bias. In all other respects th
e 
technique remains intact. 
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PRESENT VALUE OF HUMAN CAPITAL (1976) 
This slide represents the life-value curves developed by ECON utilizing the Value of 
Human Capital approach. This technique will be utilized to compute the value of extending 
life for a specified period. The procedures and assumptions used to prepare these revised 
curves are described in Appendix A. 
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SAt1PLE CALCULATION FOR THE BENEFIT OF EXTENDING LIFE TWO YEARS 
The example on page 48 illustrates the technique utilized to determine the present value
 
of future earnings out to age 90. Now let us take an example that is more similar to 
the situation encountered in this study. namely the benefit of postponing death for N 
years. In the example, we have the same white male earning $10,000 per year and afflicted 
with a disease at age 40. With present treatment, his average life expectancy is 10 yea
rs 
but with the new treatment his life-expectancy is increased to 12 years. This technique
 
is used in this study for determining the value of extending lives, but a 6 percent dis-
count factor is utilized and actual earnings data from the Department of Labor. In the 
example the social benefit is calculated as the discounted value of the two additional 
years of earnings ($10,238). This method has been used in this study in order to quantify 
the social benefit of life extension. Actual earnings data from the Department of Labor
 
and ~ I, oprcnnt rate of discount have been used in this study. 
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SAMPLE CALCULATION FOR THE BENEFIT OF EXTENDING LIFE THO YEARS 




.i. ct: ..J 
..J ~"-J 0 DISCOUNTED BENEFIT OF THO YEARS CI ,,"i' EARNINGS IS $10,238 
"-
s;:." f 0 <;:j I ~ 
'" 4,<v"i' I CI I z: 50 ~ ct: "'~ I '" => ~"-J 0 I 0 
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BE~IEF ITS OF LYMPHOCYTE SUBGROUP SEPARATION AND CLASSI FICATION 
FOR THEATMENT OF END STAGE RENAL DISEASE 
AND 
BENEFITS OF THE SEPARATION OF UROKINASE PRODUCING CELLS 
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BACKGROUND 
In a previous study for NASA Headquarters, two promlslng candidate substances for space bioproces-
sing were selected for benefit evaluations. 1 These two substances were lymphocytes and urokinase. In 
the case of lymphocytes, ground-based research has led to the classification of two subgroups, and the 
objective of the space-based research is to furthe r separate and extend the classification process 
within the two presently identified subgroups. At the present time, using ground-based techniques, 
urokinase-producing cells cannot be separated from other kidney cells. In both instances, electro-
phoretic separation in space has been proposed as the mechanism to effect separation. The clinical 
application selected for study in connection with lymphocyte subgroup classification, is the matching 
of donors and recipients for kidney transplantation; while the application selected for urokinase is 
the reduction of blood clots associated with thromboembolic diseases, specifically pulmonary embolisms. 
The referenced previous study contains a complete description of these two diseases and treatment 
systems, which is not repeated in this report for the sake of brevity. While other possible applica-
tions exi st for these two substances, these two applications represent areas where immediate progress 
could be made if the space-based research is successful. 
Thi s previ ous study concluded that very large economic benefits could result from successful lym-
phocyte subgroup sepa ration. During this study, it was also determined that it is possible that uro-
kinase production cost s could be reduced as a result of the successful separation of urokinase-produc-
ing cells, thus l e ~ding t o increased availability and widespread use of urokinase in the treatment of 
thromboembolic dis eases . This, in turn, could lead to a reduction in the number of deaths from pul-
monary embolisms , and could poss ibly reduce the need for some surgi cal procedures and thus reduce the 
length of hospital stay . 
In the present study the di sease therapy sys;:em model s for these t\~O appl ications were reviewed, 
and t he results extended to include both economi c and social benefits. 













;.. -... -! 
" 
,"~CO ''':' ,"-' . 
--_.-. -_.------ ., --- -.-. ~-.". ~~ 






I ~I' .~_J 





~. ~ I 
I ' 









----'*"""=."" =' ----..... ' '-:..--:--" --~~-.... -':::&~¥''''"'~ __ ::::::!i 
BACKGPOUtID 
• PREVIOUS STUDY OF LY1~PHOCYTE SUBGROUP SEPJl~~TIO:/ A~ID SEPAR!\~ lON OF UROKIIlASE-
PRODUCING CELLS USED A TRANSITIONAL PROBABILITY TECHtHQUE TO ESTJr1ATE ECONOt1IC 
BENEFITS 
sunST AliCE LYI'IPHOCYTES UPOKINASE 
SPACE rOOC[SS SEPflRATE AlID CLASS I FY SlI%POUPS SEPARATE MID CONCENTRATE 
UROKINASE-PRODUCING CELLS 
r1ECHAN ISM E LE CTROPHORI '; I S EL[CTROPHORISIS 
CLINICAL APPLlU,TIOtl KIDNEY TRANSPLAIITMION TIIRDMBDEMBOLIC DISEASES 
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MORE DEFINITIVE DATA COLLECTED 
To improve the reliability and accuracy of the model results in this study, additional data were 
collected about the treatment, costs and mortality rates of end stage renal disease (impacted by lym-
phocyte separation) and pulmonary embolisms (impacted by urokinase). 
~ 
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I~ORE DEFltlITIVE DP_TA COLLECTED 
TO \l4PROVE THE BErlEFIT ESTlWTIOII, DATA viAS 
COLLECTED P.ELATIVE TO: 
• END STAGE RENAL DISEASE (ESRD) 
+ TREATI1ENT 
+ COSTS 
+ W1P.TAL ITY 
• 
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MODEL DF KIDNEY DISEASE 
The treatments for end stage renal disease (ESRD) known today are dialysis and transplant. It is 
believed that through lymphocyte separation in space, a better understanding of the body's immunological 
systems will come about, resulting in better tissue matching and hence, a greater success rate in trans-
plant operations. 
Eight states are defined in the model of kidney disease. Note that all five states encircled are 
reached after contraction of ESRD. These five states were singled out for the model thereby ignoring 
healthy people and those who had kidney disease, but not ESRD. We defined a discrete Markov Process for 
these five states, dictating that each year a transition would occur. The transition could result in 
movement from one state to the next or possibly in no movement at all. 
Statistics were collected to enable the estimation of th2 potential benefits of space processing 
of lymphocyte separation. Three cases were defined with which to exercise the model: (1) current 
status, (2) partial improvement due to space pl"ocessing, and (3) optimistic improvement due to space 
processing. 
Among the statistics we collected for each case were: 
1. How long did the patient live after contracting ESRD? 
2. How many years after contracting ESRD did the patient enter each state? 
3. How many years did the patient "reside" in each state? 
4. 
5. 
Cost to public sector. 
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ESRD DATA CDLLECTION 
Recent data was obtained enumerating the number of patients undergoing dialysis and the number 
receiving transplants. The data indicate that ECON had properly modeled the treatment regimes for ESRD 
in our previous study for NASA Headquarters. I Additionally, only minor modification was necessary to 
the cost data. The cost data used in this study for treatment of ESRD is shown in Appendix B. 
Prel iminarY_.!3~!1_ei.i_t....!ona.!)'sis of Biolo9.ical Spas.e Processing. ECON, Inc., 1 September 1976 . 
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ESRD DATA COLLECTION 
LATEST KIDNEY TRANSPLANT STATISTICS OBTAINED 
MOST RECENT COUNT OF ESRD PATIENTS ON DIALYSIS OBTAINED 
COST DATA PREVIOUSLY OBTAINED APPEARS ADEQUATE 
ARTICLE REGARDING LONG-TERM TRANSPLANTATION 
c.n.lCUlATIONS LOCATED 
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TRANSITIONAL PROBABILITIES FOR END STAGE RENAL DISEASE 
Transitional probabilities can be conveniently represented through the use of a matrix. The matrix 
is arranged with the present states listed vertically on the left of the matrix and the states which can 
be entered horizontally across the top. Thus, by following the column across the matrix the probabil-
ities can be seen for entering any other state. There are certain transitions that are not possible and 
those transition boxes are darkened on the matrix in the figures (or given a value of zero). 
The transition probabilities for the treatment of ESRD were estimated through consultation with 
experts in kidney disease and kidney transplantation, and by literature review. The probabilities were 
estimated for two cases: a baseline case and an improvement case. The baseline case represents the 
present state-of-the-art for treatment of ESRD. The improvement case represents the expected improve-
ment brought about by the use of space processing to separate and classify lymphocyte subgroups. 
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TRANSITION PROBABILITIES FOR END STAGE RENAL DISEASE 
PROBABILITY MATRIX FOR BASELINE CASE 
15T Y[.<!P. CD::' T POST 
DIALYSiS OI~LYSIS TRMISP. TRAilS? DEATH 
1ST YEAR D(plYSi~ I ,) .2 .1 
cocn OIALYSIS I .92 .02 I .06 
TRAf..SPl;;:1T 
.45 I .03 .42 .10 
PGST TP:~NSPLII.~T 
.125 I .03 .B2 .025 
DEAT" i I 1.0 I t 
SOURCE: 
Prottabillty transitions deten'"ntIJ fro ... "naly!lng the statl\tlcs on thE' 
nUl'ter of persons contr4tCIng (SAO "'nnllll1y. tht nllTter receiving dldlysj~. 
th~ nllTter recehlng transplants dnd the ntlNles of tht percel'lt dying the 
ftrst yur of [SRo. SDurcn Include: 
Hou~e of RrpresenUthre1, Hur1ngS Bl!fore tile Hruse 5ubCOllllllt!!! 
on OverSl91\t on Hedlcue's End-5t'ge Renal DlSu~e Pr'}.!l!.!.I!!. (i.P.O 
June 24 - July la. 1915. 
HU10nli Dh,lylls RtIIlhtry, Hatlon.1 Institute of Arthritis ,lnd 
Met.bollc Diseases, II.I.H .• Betllesd., H.ryl.nd, October I, 1915 
Advisory COo'nIlttee of tile Renll TrilMphnt Registry, !!Je TMI!!!th_ 
Aeport of the H~n Aen,l Tr.!'spllnt R!!l!!!!'Y. J A.K.A .• August 
lB. 1915. 
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PROBABILITY MATRIX FOR IMPROVEMENT CASE 
1ST YE,I\R, CON'j POST 
OI~LYSIS OIALYSrS TRAIISP. TRM'SP. OEATH 
. 
lSi YEAR DIALYSiS I .45 .45 I .10 
CO/i'i OI~LYStS I ,79 .15 I· .06 
rll.MISPL!.I1j" 
.16 I .02 I .77 ,n5 
.05 I 
-I .o~ J.91 I .02 




Probability transitions determined after detafled discussions wfth Rogasfn 
Kidney Center medical staff and recognftion af the maximum impact to be 
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RE5UL T5 OF E5RD TREATr4ENT 5 mULATIDN 
One thousand iterations were run for the pro
bability transition mat~ices for E5RD utilizi
ng a Monte 
Carlo simulation. The results of the simu
13tion are shown in the oPPQsite chart. 
As the transplant rejection rate and t~e death rate decre
ase, the life expectancy of the average 
patient increases. The assumption was made 
that as the kidney transplant rejection rate decreases, 
more patients will elect that form of treatm
ent and thus the probability of transitionin
g to the 
transplant state was increased in the improv
ement case. Through a reduced mortality for
 transpiant 
patients, and an increase in the number of p
atients choosing that treatment, the expecte
d patient life 
after contracting E5RD vias extended by more 
than three years in the improvement case. 
Because the costs 
to both the government and the individual ar
e both less for the post-transplant state a 
reduced cost 
s ituat i on is encountered, even with the exte
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P.E,)UL TS OF ESPO TREATr1ENT SII,lIJLJI.TI!)'1 
"AGE" (A) AT :lEATH 
!/UI4BER OF 'fEIlPS I~I; 
C01ITHfJHlG DIALYSIS 
TPft';SPU~1T 
POS~ - TD,I.'ISPLAIIT 
COS~ ~!) P~BLIC SECTOR PER INDIV[DUAL O'/E~ :',~:,/::;I!,~L'S LIFE (J'1B5 DOLLARS) 
;J~I~ :Cr/;';TED Dr: '";';·.7~:; !"'; I)" 
COST TO P~IV{. :: 'U~i!)P PER JlIDI'/[DU.i'.L (I 9B5 DOLLAP~ 
WIDISCOWIT£D 
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MODEL OF PULMONARY EMBOLISM 
The current treatments of thromboembolic diseases, specifically pulmonary embolisms, are heparin 
therapy and surgery. Additionally, it is believed that the use of the drug urokinase will become an 
effective treatment regime once it receives FDA approval for use in the United States and is commer-
ciallyavailable. It is anticipated that not only will urokinase lyse, or dissolve, clots of the lungs, 
but also have the same effect on clots in other parts of the body. 
Ten states were defined for the treatment of pulmonary embolisms as shown in the opposite figure. 
For the simulation, all states were utilized except the state representing the general population. 
Statistics were collected to enable a comparison of the costs of treatment of pulmonary embolisms 
pre and post introduction of urokinase. Two cases were defined: baseline and improvement. The base-
line case represents the current state-of-the-art of treatment of pulmonary embolisms (without urokinase), 
while the improvement case represents the anticipated state-of-the-art after the introduction of urokinase 
as a therapy system. 
Among the statistics collected for each case were: 
1. How long did the patient live after contracting pulmonary embolism? 
2. How long did the patient "reside" in each state, particularly the 
post-treatment state which represents surgery? 
3. Costs to the individual. 
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THROMBon~BOLIC DISEASES DATA COLLECTION 
The data-gathering effort provided a more refined and reliable estimate of life extension 




















THROMBOEMBOLIC OISEASES DATA COLLECTION 
• DATA ON THROMBOEMEBOLIC DISEASES BESIDES PULMONARY 
EMBOLISM OBTAINEO 
• BETTER DATA ON MORTALITY FROM PULMONARY EMBOLISM 
OBTAINED 
• SOME DATA ON DOCTOR VISITS AND HOSPITAL STAYS 
OBTAINED 
• IMPROVED DATA INPUTS WILL ALLOW MODEL TO GENERATE 
MORE ACCURATE ESTIMATES OF: 
+ YEARS OF LIFE EXTENDED 
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Transition probabilities were determined for the treatment of pulmonary embolisms through con-
sulting with experts familiar with urokinase efficacy and by analyzing the literature on pulmonary 
embolisms. The sources of the transitional probabilities and the costs for treatment of pulmonary 
embolisms are shown in Appendix C. The transition probability matrices are given for the two cases 
as shown on the opposite page. 
Cost estimates are based on actual experience in the case of a surgeon's fees, and on an approx-
imation based on costs in other countries in the case of urokinase. The degree of severity of an embolism 
determines costs and the range is great. One patient may need surgery followed by intensive care while 
another patient may be treated medically, only to have to undergo surgery later. 
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The probability matrices for pulmonary embolism were run utilizing a Monte Carlo simulation tech-




The small increase in age at death of 1.56 years between t~e baseline and improvement cases is 
attri butabl e to tile fact that 11% of the pul mona ry embo 1 i sm cases result in immedi ate death, and that 
a very significant number of pulmonary embolisms are not diagnosed and do not receive treatment. I. 
.. ,1 
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INatural Histort of Pulmon~ Embol .. ism. James E. Dalen and Joseph A. Alpert, "Progress in 
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RESULTS OF PUU10NARY EMBOLISM TREATMENT SIMULATION 
BASELINE CASE IMPRO\lEMENT CASE i 
MEASURE MEAN MEAN , 
! 
"AGE" (Al AT OEATH 20.33 21.89 I 
--
i NUMBER OF YEARS IN 
POST P. E. ,I/OUT PROPI'IYLAX IS 10.57 11.25 , POST P.E. WITH PROPI'IYLAXIS 6.45 7.24 
, COST TO PR I VAT[ SECTOR PER INDIVIDliIAL 
I 
OVER IfIDIVIDUAL'S LIFE (~l 
UNDISCOUNTED 18.332 19.255 01 SCOUIiTE D AT 6" 9.095 9.180 
-
(Al THROUGHOUT "AGE" I S MEANT TO BE TEARS AcTER CONTRACTING P. E. 
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Sl!JMMARY OF BENEFITS OF TREATMENT FOR ENO STATE RENAL DISEASE AND PULMONARY EMBOLISMS 
The ECON-developed medical treatment simulation model comJ!)utes the expected 1 ife spa,n of a patient 
cantracting the disease in question and the expected costs to ane average patient. It is estimated that 
there are 10.000 new ESRD patients each year and 750.000 cases af pulmana,ry emlllol ism occur each year 
(whether diagnosed or not). The oppasite bble shows the benefits accruing to the graup entering the 
disease state in one year. If no new treatment technique comes along. these benefits would accrue to 
those contracting the particular disease each successive year. 
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SUMMP.RY OF llENEFITS FOR TREP.TMENT OF END STP.GE RENP.L DISEP.SE P.NID PULMONARY EMBOLIS
MS 
BENEFITS TO DISEASE AS A RESULT OF NEW TREATMENT TECHNIQUES 
TYPE C,F BENEFIT PULMONARY EMBOLI St1 END STAGE RENAL DISEASE 
ECONOMIC (DECREASED -$112.9 MILLION (OVER A 22 GOVERNMENT: $879.65 MrLLION F
OR 
COST FOR EQUAL YEAR PERIOD) TO PEOPLE CON- THOSE ENTERING TREATMENT IN
 ONE 
IF- CAPABILITY) TRACTING P.E. DURING ONE YEAR (TAKES 
17.11 YEARS TO REAL-
t ~O 
YEAR (THIS COST COULD ALSO IZE BENEFITS) 
ACCRUE TO PEOPLE ENTERING 
THE SYSTEM EACH SUCCESSIVE PRIVATE: $96.73 MILLION FOR 
YEAR)* niOSE ENTERING TREATMENT DURING ONE YEAR (WOULD TAKE 17.11 YEARS 
r 
J ,. 
TO REALIZE THE SAVINGS) 
I 
I , 
SOCiP.L (EXTENIlED AVERAGE CAPITALIZED VALUE OF ASSUMING THAT 50 PERCENT OF THOSE 
r~EAN LIFE EXPECTANCY EARNINGS FOR L 56 YEARS FOR WAD WORKED CAN RE
TURN TO WORK THE 
: 
. ,'1 
ONCE DISEASE IS CON- 750.000 PEOPLE IS $3.103 CAPITALIZED VALUE OF 3.39 YE
ARS 








*COST OF TREATMENT WITH UROKINASE EXCEEDS COST OF PRESENT TREATMENT 
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TYPES OF O;IABETES MELLITUS 
Generally speaking, there are two types of diabetes mellitus: adult-Gnset and juvenile-anset. 
Adult-Gnset diabetes is frequently and increasingly being cGntralled by diet manipulation and aral 
hypoglycemic techniques; these diabetics a're typically not insulin-dependl'nt. Juvenile-anset 
diabetics, on the other hand, typically are insulin-dependent and wauld benefit fram any technalo-
gies which cauld improve insulin therapy, either the process of introduction of insulin into the 







IttL~...:.~. Ja1sj ).:,;;:~~:-:!'·_"r:.::::.:;: .;6L%5&:'I1·:P,p'rti'%&&fZ;iA':ir". r ·:;<;"-":')=:;~fW"'·h*'N(·!ti'-i;.:tibiiei4_ef6;,·~f:#ttti,ig*"jtiij;?"'(ki$t*k'met&&i+ ,Q ',- iWr , .... 'to :'''k,'-li''- ~, -.- "~~ ~ ',-, ·.·,·~t_ • '-, ;J WAiWn nUSil!fi V;-OfT! YEm},ri'ii&N£bMRW~'iSW- ~M:l!('*" g;;'k'itf'Mf4~ 
r 








- --.----------. _.- ---
.. ,--- ---~------~-. , . 
--------.---~ 
TYPES OF OIABETES MELLITUS 
• ADULT ONSET (INSULIN- INDEPENDENT) 
+ ONSET USWALL Y AFTER 40 
-~---
+ GErlEAALLY CONTROLLED BY DIET AND/OR ORAL HYPOGLYCEMIC 
AGENTS 
+ HIGH INCIDENCE OF CORONARY COMPLICATIONS 
• JUVENILE ONSET (INSULIN-DEPENDENT) 
+ ONSET USWALL Y BEFORE 25 (90%) 
+ REQUIRES l!ISE OF INSULIN 
+ HIGH INCIDEtlCE OF KIDNEY ANI!) EYE COMPLICATIONS 
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DIABETIC PATIE':T POPULATION OF THE UNITED STATES 
Of the 1.24 mi11ior insulin-dependent diabetics in the United States today 85 percent are 
thought to have had diabetes anset between 0 and 19 yea,rs af age, 5 percent between 20 and 39 
years, 5 percent between 40 and 59 and 5 percent at age 60 or more. 
Further. the papulation is: 
33.0% White Male 
52.2% White Female 
5.7% All Other Male 
9.1% All Other Female. 
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CAUSES OF DIABETIC DEATHS: 1897-1968 
The rapid growth of insul in therapy in the early part of this century greatly decreased the 
i,ncidence of di,abetic coma. lne problem of survival of the d'iabetic became not one of immediate 
complications (that is. coma). but of long-term complications. Juvenile-onset diabetics could 
be expected to funcUon .1ormally in society up to the point where the long-term complications. 











































































. .... -. e_._._._ 
189/~ 1914- 1922- 1937- 1944- ;9:'0- 1960-
1914 1922 1936 1943 1949 1959 
1968 
326 836 ~. 157 3.639 4.148 9.851 
5.009 
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MAJOR COMPLICATIONS OF BIABETES 
All of the major. known complicaUons of diabetes were considered in this study. Several of 
these--neuropathy, ketosis, allergy and visual impairments o'Lher than diabetic retinopathy--were 
no,t explicitly modeled because their effects were not sufficiently significant, because not enough 
was known about the complicaUon, or because it was felt that the improvements being studied would 
not impact the complication. The major complications--diabetic retinopathy. nephropathy, cardio-
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tl 1. DIABETIC RETINOPATH¥ - MODELED r • 2. OTHER VISI!JAL (GLAI!JCIilMA, CATARACTS) - EFFECTS NOT SIGNIFICANT 
~ 3. NEPHROPATHY 
- MODELED , 
; I. 4. CARDIOVASCULAR - MODELED 5. NEUROPATHY 
- INSI!JFFICIENT MTA ! 6. PERIPHERAL VASCULAR 
- MOl!lELED ~ 
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After consulHng with medical contacts' and reviewing relevant medical literature. it was 
assumed far the modeling effort that 50 percent of all complications a,rose from imperfect control 
of bIood suga'r levels. 25 percent were due to antibody build up to foreign insulin and 25 percent 
to other unknown factors. These estimates renect the degree of agreement among the expert medical 
community. That is. while virtually all physicians agree that complications arise from poor control 
of di.abetes. fewer believe that antibody production or other unknown factors are si'gnificant causes. 
In most ca'ses this lack of agreement takes the form of uncertainty rather than disagreement. 
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ANfMAL INSULIN: EXPECTEIil CHANGES IN SUPPLY AND DEMAND 
The supply af animal insulin is expected to became :nare expensive in the future. This is due to 
the fact that the removal af the pancreas fram cattle and hog carcasses is labor intensive and meat 
packers are re$isUng the perfarmance of this function. On the other hand, the incidence of diabetes 
in the t1nited States is inc'reasing at abaut 6 percent per yea,r, thus creating greater demand pressures 
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+ INCREASED COST OR REDUCTION IN 
PRODI!JCTION EXPECTED 
DEMAND 
+ INCREASED DEMAND EXPECTED DUE TO RISE IN 
INCIDENCE OF DIABETES BY 6", PER YEAR 
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POSS IBLE TREATMENTS OF lilIABETES 
ECON medeled several possible treatments of diabetes, including the most commonly used now: 
injection of foreign insulin. The problem of build-up of antibedies could be overclilme by the use 
of "human" insulin, taken directly frlilm human pancreas, cultured from I}eta cells extracted from 
human pancreas, synthesized, or prlilduced from E. col i bacteria. Space bioprlilcessing can assist 
the extractien of insul in er Beta cells from the human pancreas by p,rov;ding a superier environ-
ment fer electrophlilresis. Either foreign er human insulin ca,n be used in clilmbinatililn with an 
implanted device known as an artificial pancreas which menitlilrs the insulin level in the body 
and secretes insulin as necessary on a centinual basis. The extraction ef Beta cells from the 
buman pancreas offers the possibility that these cells can be injected into and accepted by a 
diabetic patient. If successfully accomplished, this ceuld eliminate the prlilblem of dia'betes. 
In extreme cases, pancreas transplants may be warranted; this would nlilt be a prima:ry form Iilf 
treatment. however, because the survival rate of such transplant paUents is extremely llilw. 
Other forms of treatment, such as hormone centrlill, were nlilt medeled either due to insufficient 
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POSSIBLE TREATMENTS OF DIABETES 
CONVENTIONAL 
*Ht:lMAN INSI!JLIN 




_ INJECTION OF FOREIGN (BOVINE, PORCINE) INSULIN 
_ FROM CWLTUREID BETA CELLS 
SYNTHESIS OR E. COLI 
_ MONITORING AND SECRETING FOREIGN INSt!JLIN 
_ MONITORING AND SECRETING Ht!JMAN INSt!JLIN 
_ TRANSPLANT OF SEPARATED INSULIN-PROOUCING CELLS 
_ DUE TO COMPLEXITY AN(iJ LIMITEID SIilCCESS MO(iJELE(iJ 
ONLY AS A TREAmENT F(i)R MI!JLTIPLE COMPLICATIONS 
OTHER HORMONE CONTROL - NOT MOOELED (iJUE TO INSUFFICIENT INFORMATION 
* POTENTIALLY IMPACTABLE BY SPACE BIOPROCESSING 
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TIME 1'0 ASSESS SlJCCESS OF TREATMENT 
Even if human insulin and artificial pancreas techniques a,re devel,eped, the actual proef ef 
their success will require many yea,rs ef evaluatien. This is because we a,re dealing with 1eng-
run cemplicaUens. The effects of treatment begun now on a juvenile diabetic cannot be assessed 
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BETA CELLS ISLETS OF THE LANGERHANS--SIMPLIFIE!l ILLUSTRATION OF THE !lISEASE TIffERAPY MO!lEL 
As a simplified illustration of the mlildel. a healthy persliln can be found tlil have insulin-dependent 
diabetes. !!Ie then acquires seme flilrm of treatment and stays with that treatment (unless he has a 
successful Beta cell transplant in which case he is "cured") until he either dies er develeps some 
complicati'on. The cemplicatien persists (generally diabetic cemplicatiens a're not curable) until the 
patien,t di,es or enters a state ef severe. or life-threatening. complicatiens. At this peint a pancreas 
transplant is considered if it is deemed likely that the patient's life can be extended. The terminal 
state is. ef course. death. Altheugh ne,t shewn. the patient centinues with the same diabetic therapy 
threughout his life (unl'ess he has a successful Beta-cell transplant). Our model assumes steady state 
conditions. dealing with new patient populatien. Because of the steady state Ilature of the model we 
assume that once a patient enters a given treatment regime that he remains in that regi,me for the re-
mainder ef his life. The best available treatment at the time of onset will always be sele.cted. 
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, SPACE B IOPROCESS I,NG 
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DIABETES TRANSITIONAL PROBABILITY MODEL 
The transitional proba,bility model performs as follows: an insulin-dependent patient is sel,ected 
from among the four age-of-onset classes shown. A treatment is selected and the individual's prog.ression 
through life is simulated. At any point in time (time is incremented in five-yea,r steps) the individual 
has a specified probability of contracting any of the complications modeled, or of dying. Any or all 
complications can be contracted before death. If the individual has several complications, yet is young 
enough to wairrant a pancreas transplant this is an addiUanal possible state before death. The madel 
works iteratively, selecting many paUents from each age-of-onset class. 
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AGE AT ONSET 
( INPUT) 
o - 19 
20 - 39 
40 - 59 
60 + • 
-_._--------"._-----_. __ . - _. __ .. _--_. 





















AIDIDIT HlNAL t I STATES 
PANCREAS TRANSPLANT 
DEATH 
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PREVALENCE OF CAROIOVASCULAR COMPLICATIONS AMONG IDIABHICS ANID GENERAL POPI!JLATION 
Improvements due to superior therapy reduce the incidence of any particula,r complication among 
the diabetic population. Improvements beyond the typical, nondiabetic individual are not cllnsidered. 
The diffe·rence in the prevalence Ilf any cllmplication between the di,abetic under conventional treatment 
and the nllndiabetic is shllwn as /}, in the Ilpposite figure. This distance is assumed to be reduced by 
dHfe·rent amounts (by 25 percent fllr the dashed 1 ine shllwn) according to the treatmen,t type and the 
complicaUll1l involved. 
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PREVALENCE OF CARDIOVASCI!JLAR COMPLICATIONS 
AMONG DIABETICS AND GENERAL POPULATION 
~ DIABETIC INIDIVIDUAL 
REDucnON IN f:, RESIUING 
FROM NEW TREATMENT 
• ~ (AGE AT ONSET: 10 YEARS) 
___ ".-T ..--
__ ... ____ HYPOTHETICAL DIABETIC 




I!JSING HYMAN INSULIN 
./ ~.----- NONIDIABETIC 
I NO I V IIDUAL 
----_.--_ .. -.-
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ASStlMEIil IMPROVEMENTS OI!JE TO IMPROVED TREATMENTS IN 
PREVALENCE OF IilIABETIC COMPLICATIONS 
The intreductien of the treatment ef diabetes with human insulin will reduce the cemplicatiens 
ef diabetes by alleviating the preblem ef the preduction of antibodies te fereign insulin and perhaps 
by previding better centrel of bleod suga'r levels. The chart presented here shews the expected reduc-
tien ef preva],ence of complications in the diabetic populatien relative te the nermal pepulatien, the 
A from the previol!ls figure. This is not the same as reducing the absolute prevalence ef cempHcatiens 
by the given percent in that the cemplicating diseases do eccur in the general pepulation and it is 
not expected that threugh the use of human insuHn er any other treatment of diabetes, diabetic preva-
lence ceuld be reduced below the l,evel enceuntered in the general pepulatien. Because ef the uncer-
tainty in the medical prefessien as to the cause of diabetic cemplicatiens, twe estimates of the pessible 
reductions, "epUmistic" and more "realistic" reductions, have been assigned far human insulin treatment. 
The treatmen't of diabetes with a Beta cell transplant is assumed te reduce the prevalence ef 
cemplicating diseases to the level ebserved in the nermal populatien. 
In either case, since insulin resistance is seen te be totally the result to antibody binding 
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ASSWMEa IMPROVEMENTS IN PREV!ALENCE OF DIABETIC COMPLICATIONS 
DUE TO IMPRIDVEo TREAliMENTS 
PERCENTAGE REIDUCTION IN 6 (SEE PAGE 111) 
ARTIFICIAL f-ANCREAS--
HUMAN INSULIN ARTIFICIAL 
HI:JMAN INSULIN 
PANCREAS--
OPTIMISTIC REALISTIC FIDRErGN INSI:JLlN 
OPTIMISTIC REALISTIC 
25 17.5 50 
75 62.5 
50 75 62.5 
CARDIOVASCULAR 25 12.5 75 50 
NEPHROPATHY 50 25 
25 
PERIPHERAL 
VASCUlLAR 25 12.5 
50 75 62.5 
INSULIN 
RESISTANCE 100 100 
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The age at anset af the individual as well as the best available treatment a,re selected and input 
inta the madel. The madel cantains prababilities af maving fram any state ta anather as a functian Gf 
time. Casts of treatment alld casts of complicatians (direct and indirect) a,re calculated as the indi-
vidual p.rogresses. The casts af death bilsed an the amount af praductive lifetime faregane are also 
included. Far each patient the tatal costs a,re calculated and averaged acrass individuals and age-
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• INPIIT REQUIREMENTS , 
+ AGE OF PATIENT AT ONSET OF DIABETES 
+ TREATMENT TYPE 
• INCORPORATEII IN HOIIEl 
+ INCIDENCE IIF COMPLICATIONS BY AGE AT ONSET ANII DIlRATION 
OF IHABETES 
+ COSTS OF TltEATMENT BY TYPE 




+ MORTALITY RATES BY COMPLICATION ANI]) ASSOCIATEII COSTS 
+ ElIPECTED IMPROVEMENT IN MORTALITY AND MORBIDITY IIIDE 
TO TREATMENT TYPES 
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THE ASSUMPTIONS 
• 
THERE IS NO POSSIBILITY OF CHANGING FROM ONE TYPE OF TREAliMENT T(i) ANOTHER; IT 
IT ASSl!JMEID THAT ONCE A TREATMENT IS SELECTEO, THE PATIENT WILL FOLLOW THE SAME 
TREATMENT l!JNTIL DEATH 
• THE Hl!JMAN CAPITAL APPROACH TO THE VAHlE OF EXTENElINC PROElUCTIVE LIFE IS 
ASSWMm 
• COSTS, BOTH DIRECT ANEl INElIRECT, ARE IHSCOtlNTm AT 6 PERCENT TO OBTAIN 
PRESENT VALl!IE 
• BENEFITS ARE INFLATED AT A CONSTANT RATE OF 6 PERCENT TO 1985, THE ASSl!IMED 
FIRST YEAR OF TREATMENT BENEFITS 
• 50 PERCENT OF COMPLICATIONS ARISE DUE TO IMPERFECT CONTROL OF BLOOD SUGAR 
LEVElS, 25 PERCENT TO ANTIBOOY BUILD-l!IP AGAINST FOREIGN INSULIN, ANID 
25 PERCENT TO OTHER l!INKNOWN FACTORS 
• COSTS OF TREAliMENTS AND COMPLICATIONS ARE SHOWN IN APPENIDICES F AND G 
• 25 PERCENT OF THOSE PATIENTS WITH THREE COMPLICATIONS UNDER 60 YEARS OF AGE 
RECEIVE PANCREAS TRANSPLANT, 35 PERCENT OF THOSE l!INDER 60 YEARS WITH FOUR OR 
MORE COMPLICATIONS RECEIVE PANCREAS TRANSPLANT 
• 70 PERCENT OF THOSE RECEIVING A PANCREAS TRANSPLANT OlE WITHIN THE FIRST 
FIVE-YEAR PERIOD, THE REMAINIDER DIE IN THE NEXT FIVE-YEAR PERIOD 
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MAJOR DATA SOURCES 
The majar sources of infonnation for the model fonnulation and description of the diabetic 
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MAJOR DATA SOIDRCES 
• INFORMATION SOURCES 
C.J. VAN OSS - STATE UNIVERSITY OF NEW YORK 
M. MACGILLIVRAY - BUFFALO CHILDRENS HOSPITAL 
W. CHICK - JOSLIN CLINIC 
D. lolARTlN - MASSACHUSETTS GENERAL HOSPITAL 
J.S. NAJARIAN - I:INIVERSITY OF MiINNESOTA 
• STATISTICAL SOIDRCES 
REPORT OF THE NAnONAL COMM!ISSION ON DIABETES ro THE CONGRESS OF liHE UNnED STATES. 
NATIONAL INSTlnlTES IDF II£ALTH 
D'IABETES MELLITUS. NATIor:!\L INSTIliUTES OF HEALTH 
DiIABETES SOURCE BOOK. U.S. PUBLIC HEALTH SERVICE 
JOSLIN'S O,IABETES MELLITUS. MARBLE. ET AL. 
CHANGES IN THE COSTS OF lREATMENT OF SELECTED ILLNESSES. SCIliOVSKY AND MCCALL 
THE ECONOM'IC COST OF ILLNESS REVISITED, COOPER AND RICE 
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TRANSITION PROBABILITY TABLE FOR CONVENTIONAL 
TREATMENT FOR RETINOPATHY 
For each complication. the probability of incidence. P (T). (assuming that the complication was 
not present in the last Ume interval) is specified as a fu~ction of age anset and duraUon af diabetes. 
A separate probability transiUon table exists for each type af treatment. as well as each complicatian. 
The prabability af dying. P2(T). is simila,rly modeled as a functian af the number of complicaUans 
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TRANSITION PROBABILITY TABLE FOR CONVENTIONAL 
TREATMENT FOR RETINOPATHY 
DURATION OF DIABETES (YEARS) 
5 10 15 20 
0.00 0.07 0.16 0.t1 
0.03 0.07 0.22 0.36 
0.04 0.22 0.13 0.23 
0.11 0.15 0.07 D.ID6 
~ 
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STATISTICAL DATA SOURCES FOR TRANSITIONAL PROBABILITY 
MATRICES OF CONVENTIONAL TREATMENT 
The literature on diabetic cemplicatiens was thereughly searched in order te ebtain data fer the 
transition prebability tables. A list of the primary data seurces is presented . 
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STATISTICAL MTA SOURCES FOR TRANSITIONAL PROBABILITY 
MATRICES OF CONVENTIONAL TREATMENT 
Oi,abetes and Its Management, W. G. Oa,k1ey, O. A. Pyke and K. W. Taylllr, 
Blackwell Sci·entific Publications, Landan, 1973. 
Pra!einuria (Nephropathy) 
"The Ki dney a'nd Renal Tract, 01 J. S. Cameran, J. T. 1 re 1 and and P. J. 
Walters in Comp1;catians af Diabetes, H. Keen and J. Ja,rrett (Editors), 
Edwa,rd Arna 1 d, Landon, 1975. 
Cllrana'ry Artery Oi sease (Ca.rdiavascu1 a,r) 
Diabet.es a,nd Its Management, Oakley et al. 
"Differences in Cardi'avascu1ar Mllrbiditv and MIll.rta1ity Between Previlllusly 
Knlllwn and Newly Diagnased Adult Diabetics," J. B. Hermaill, J. M. Meda1ies 
and U. Glll1dbourt, Diabetalogia 13, 229-234, 1977. 
Peripheral Vascu1a'r 
"Scope and Impart of Oia,betes (I I}," 
Reo.ort af the National Cammission on 111, Part 2, 
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EXAMPLE OF THE IilPERATHiIN OF THE O,IABETES T
RANSInONAL PROBABILITY MGDEl 
Consider some individual patient from one of
 the classes of age-of-onset. I)uring each period of 
time, he has a specifi,ed chance of contractin
g each of the compHcaUons--unl,ess he alrea
dy has the 
complication, in which case he keeps it unti
l death. The costs of treatment as well as t
he morbidity 
costs (e.g., absence from work or inability to work) ar
e calculated peri,od by pedod. At some poin
t 
the indiv;dual di'es, at which time a mortalit
y cost, which is the income foregone for the
 remainder 
of the expected 1 ifetime of the nondiabetic 
i'ndividual, is added. All costs a,re appropd
ately dis-
counted (6 percent is used as the discount rate) and sU
Ol11ed to obtain a present val'ue cost associate
d 
with that paUent. 
The sample patient shown opposite incurs no 
complications in the first five-yea,r perH,d; 
but is 
affHcted with nephropathy in the second five
-year interval. In the next interval, no ne
w complica-
tion evidences although nephropathy persists.
 In the fourth pedod, the sample patient is
 afflicted 
with both retinopathy and peripheral vascula
r complications. All complications i,ncurred 
pe,rsist and 
in the sixth period a pancreas transplant is 
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EXAMPLE OF nfE OPERATION OF THE DIABETES TRANSITIONAL PROBABILITY MIilIilEL 
TREATMENT ANm .. I.. MORTALITV COST MORBImnv COST 
tl. tl. A: .:.:?:.:-: :,:'.::.::. ;::,;..~\::: ;.:::~:,;t:: ~·.:,;js:: ::.::;;::1 
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tl. tl. tl. 
15-21il 20-25 25-30 











A POSSIBLE DEVElOPl1ENT 
• IHIHAL OO~U"ENCE 
c::J COST lN~U"[O 
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COST OF DIABETES TREAliMENT 
Costs of treatment in 1976 dallars a,re presented far the initial five years after anset and for 
each five-year periad follawing. Three cost levels (#1. #2. #3) are given for the costs af obtai1ning 
human insuHn since mare specific information is nat avanabl,e at this time. Appendix F presents these 
costs in cansiderable detail. The distincUan between the "optimistic" and "realistic" cases refe,rs 
nat ta cost distinctians but ta the impravement in camplicaUons beHeved passible as discussed on 
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COST OF DIABETES TREATMENT 
* 
FIRST 5-YEAR PERIOD ADDITIONAL 5-YEAR PERIODS 




HUMAN INSULIN #1 OPTIMISTIC 3080 
2665 
H\!JMAN INSULIN #1 REALISTIC 3080 
2665 
HUMAN INSULIN #2 OPTlMISTlC** 3630 3765 
HUMAN INSULIN #2 REALISTIC 3630 
3765 
HUMAN INSULIN #3 OPTIMSITIC** 4318 
5140 
HUMAN INSULIN #3 REALISTIC 4318 
5140 
ARTIFICIAL PAlICREAS/FOREIGN * 22695 
11075 
ARTlFlCIAL PAIICREAS/H\!JMAN //1* 
OPTIMISTIC 22695 
11075 
ARTIFICIAL PANCREAS/H\!JMAN #1 
REALISTIC 22695 
11075 
ARTIFICIAL PANCREAS/HWMAN #2** 
OPTIMISTIC 23355 
12175 ~~ ARTIFICIAL PJl,NCREAS/I'IUMAN #2 
REALISTIC 23355 
12175 82 ARTIFICIAL PANCREAS/HUMAN #3** 
OPTIMISTIC 24380 
1355Q 1ltIE: 
ARTIFICIAL PANCREAS/HUMAN #3 
REALISTIC 2438(i) 13550 
€"I:I 
BETA-CELL TRANSPLANT 7092 
618 E=~ 
PANCREAS TRANSPLANT 30098 
25500 ~: 
* COST OF DIABETIC TREATMENT 
** S[F APPFfIDIX F FOR VARIATIONS IN COST OF HUMAN INSULIN, COST LEVELS #1, 2 AND 3 
U$ J1) 
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COST OF DIABETIC COMPLICATIONS 
** FIRST 5-YEAR PERIOD 
COMPLICATION ($/PATIENT) 
RETlNOPATHY $ 625 
CARDIOIIASCWLAR DISEASE 9,940 
PERIPHERAL VASCULAR DISEASE 20,500 
NEPHROPATHY 2,500 
INSULIN RESISTANCE 14,433 
* SEE APPENDIX G FOR COST BREAKDOWN AND SmJRCES. 
** COST OF TREATMENT AND MORBIDITY 
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PRESENT VALUE OF EC@NOMIC AND SOCIAL COSTS BY TREATMENT 
FOR PRESENT DIABETIC POPULATl(iIN 
If one were to consider the present diabetic population. one could use the medel discussed herein 
to estimate the tetal costs attributable to diabetes in its present state. This is done in standard 
Mon,te Ca,rIo fashi.en by running through the medel many patients in each age-of-onset cla·ss and then 
averaging to fi,nd an average cost per patient for each class. This average is then multiplied by the 
number of pati,ents in each class in the current patien·t population. These costs. sunrned across 
c1.asses. aire presented here for each treatment type. Econemic costs are direct expenditures fer 
treatment. beth for diabetes and comp1 icati<ons. while social costs refer te werk days lest and 
reduced productive lifetime. 
The doHa.r value represents 1985 dollars which are calculated from 1976 dollars using a 6 percent 
rate of inflaUon. 
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PRESENT VALUE OF ECONOMIC AND SOCIAL COSTS BY 
TREATMENT FOR PRESENT DIABETIC POPULATION 
TOTAL COSTS ECONOMIC COSTS SOCIAL COSTS 
(1985$, r~ILLIONS) (1985$. r~ILLIONS) (1985$, MILLIONS) 
CONVENTIONAL 34466.9 59112.3 
93579.2 
HtlMAN INSI!ILIN #1 OPTIMISTIC 28974.1 53605.1 
82579.2 
HUMAN INSULIN #1 REALISTIC 32724.7 55156.3 
87881.0 
HUMAN INSI!ILIN #2 OPTIMISTIC 34255.7 52939.7 
87195.4 
HtlMAN I NSIlILlN #2 REALI STI C 38270.9 54810.8 
93081.7 
HI!IMAN INStlLlN #3 opnMISTIC 41011.4 52613.8 
91936.4 
HillMAN INSULIN #3 REALISTIC 43689.4 57035.5 
100724.9 
IIRTIFICIAL PANCREAS/FOREIGN 99425.8 49346.1 
148772.0 
ART. PAN./HUWl,N #1 OPTIMISTIC 94477 .4 47178.7 
141656.1 
ART. PAII./HUMAN e1 REALISTIC 95741.4 51745.9 
147487.1 
ART. PAN./Hur~AN #2 OPTIMISTIC 100152.8 * 46815.1 146967.9 
ART. PAlI./HUMAN #2 REALISTIC 102367.6 47580.3 
149947.8 
ART. PAN./HUMAN #3 OPTIMISTIC 107634.9 48069.6 
155705.4 
ART. PAII./HUMAN #3 REALISTIC 108166.5 47695.2 
155861.7 
BETA-CELL TRANSPLANT 20778.2 43211. 5 
63989.7 
* COST ASSUMEID EQUAL TO PPESENT 
KIDNEY TRANSPLANT COSTS 
** ASSUMES 50 PERCENT REDUCTION OF TREATMENT COSTS 
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PRESENT VALUE OF 8ENEFITS OF TREATMENT IN COMPARISON TO CONVENTIONAL 
TREATMENT FOR PRESENT U.S. IiIIABETIC POPtJLATION 
Some. but not all. of the alternative treatments modeled compare favorably with the current, con-
ventional treatmen,t. Direct injection of human insulin can provide a present value benefit of up to 
$11 billion (1985 dollars) or a disbenefit of $7.1 billion, depending upon the assumptions employed. 
The advantages of the artificial pancreas appear to be subtantially outweighed by its cost; given ou,r 
estimated inputs to the model. the artificial pancreas is clearly not economic. Beta cell transplants. 
if avanabl'e at the reasonable costs assumed (see Appendix F). a,re extremely beneficial; thi s treatment. 
if successful, effectively eliminates the problem of diabetes for the patient. 
Of course, space bioprocessing is only one possible means of obtaining these benefits. Laboratory 
synthesized human insulin, fer exampl,e. may result even without space bieprocessing. 
Thus. the benefits shown are really the benefits of the improved treatment and a,re independent of 
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PRESENT VALUE OF BENEFITS OF TREAlMENT IN COMPARISON TO 




CONVENTIONAL (BOVINE/PROCINE INSULIN) 
HUMAN INSULIN #1 OPTIM;JSTIC 11.0 
HUMAN INS!:JLIN #1 REALISTIC 5.7 
HUMAN INSULIN #2 opnM,Isnc 6.4 
H!:JMAN INS!:JLlN #2 REALISTIC 0.5 
HUMAN INSULIN #3 OPTIM'ISTIC 1.7 
HI!1MAN INSULIN il3 REALISTIC -7.1 
ARTIFICIAL PANCREAS/FOREIGN -55.2 
ART. PAII./HUMAN #1 OPTIMISTIC -48.2 
ART. PAtI./HUMAN ill REALISTIC -53.9 
ART. PAN./HUMAN 12 OPTIMISTIC -53.4 .. 
ART. PAN./HUMAN 112 REALISTIC -56.3 
ART. PAN./HUMAN #3 opnM'ISTIC -62.2 
ART. PAN./HUMAN #3 REALISTIC -62.3 
BETA-CELL TRANSPLANT 29.6 
.. COST ASSl:JMED EQl:JAL TO PRESENT 
KIDNEY TRAtlSPLANT COSTS 
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BENEFITS OVER CCilNVENTIONAl TREATMENT 
DIRECT AND INDIRECT COSTS 
------------~ .. ---~.~,---
The opposite figure plots the expected be,nefits of each of the treatments considered relative 
to the conventional treatment (bovine/porcine insulin). 
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SI!JMMARV OF BENEFITS OF BETA CELL TRANSPLANTS 
Presented here are more detailed results from the Beta cell treatment case. The number of dia-
betics in each age-of-onset class is listed as well as average age at death and the benefits of the 
treatment when compa,red with the conventi,onal. As can be s\~en. the patients I lifetimes always increase. 
The largest benefit. of course. comes from the youngest age-of-onset class. primarily because of the 
large population size of that class. but also because theirs is a lOllger diabetic lifetime to be affec-
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SUMMARY 0F BENEFITS OF BETA CELL TRANSPLANTS 
NUMBER IN BENEFITS TO BENEFITS TO BENEFITS TO TOfAL 
~E AT U.S. POPULATION TREATMENT COSTS COMPLICATION MORTALITY COSTS BENEFIT 
DIA8ETES ONSET (MILLIONS OF AVERAGE ~E IMILLIONS OF COSTS (MIH IONS (MIHIONS OF (MILLIONS OF (YEARS OF AGE) PERSONS.) AT DEATH DOLLARS)" OF DOLLARS)" DOLLARS)" DOLLARS)" 
o - 19 1.06 47.7 (41.9) 6667 4967 1503-1 26665 
I 
20 - 39 .06 64.6 (60.3) 365 329 559 1255 
40 - 59 .06 73.6 (71.2) 282 485 335 n02 
60* .06 76.0 (75.9) 220 367 19 568 
TOTAL··· 1.24 51.1 (45.9) 7542 6148 15944 29633 
- ------- _L- -
• AVERAGE AT DEATH, BHA CELL TRANSPLAIIT (AVERAGE AG~ AT OEATII, CONVENTIONAL 
tREATMENT) 
•• PRESEN~ VALUE IN 1985 DOLLARS 
••• DI'fFERENCES BETWEEN COLUMN TOTALS AND TOTAL ROW ARE DUE TO ROUNDING ERRORS 
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PRELIMINARY FINDINGS 
Our preHmina.ry results show that there may be substantial benefit from the production of human 
insulin or the separation of Beta cells for transplantation. These benefits could be in the range of 
$11 billion (19B5 dollars) to $29.6 billion (1985 dolla,rs). Considerably more information on the costs 
of human insulin production or Beta cell separation must be obtained, however, before we can have con-
fidence in the size of the ultimate benefit. Hopefully more information and consensus on the effects 
of insulin-antibody build-up in the body will also be forthcoming from medical researchers. 








































• PROD~CTION OF all/MAN INSULIN 
+ POTENTIAL ECaNOM'IC AND SaCIAl BENEFITS MAY BE lARGE 
+ IMPROVED ESTIMATES OF COST OF PRODUCTION OF INSULIN AND 
IMPACT OF HUMAN INSULIN ON IHAB'ETlC COMPLICATIONS REQl!IIRED 
TO REDUCE l!INCERTAINTY IN BENEFIT ESTH1ATES 
• BETA-CELL TRANSPLANT 
+ LARGER POTENTIAL ECONOMIC AND SOCIAL BENEFITS 
+ SHORTER TIME REQl!IIREO TO ASSESS BENEFITS 
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HUMAN CAPITAL PROCEDI!JRES/ASSIJMPTIONS 
• Mean earni,ngs of full-time, year round employees obtained from llepa,rtment of Labor, Monthly Labor 






All Other Men 
White Women 





Full-time employees represent the following percentage of all persons with work expedence: 
WMte Men 
A 11 Other Men 
White Women 





Thus, this percentage was multiplied Umes the respective earnings. 
Mean ea,rnings figures a,re then adjusted upward to account for wage supplements (employer contribu-
tions for social insurance, private pension and welfare funds). The uniform factor is 1.0776. 
seventy percent of $4,000 was added to all women's ea,rnings for housekeeping services: $400 was 
added for all males. $4,000 was imputed as housekeeper earnings for all retired females and $1,000 
for men. 
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HUMAN CAPITAL PROCEDURES/ASSUMPTIONS (Continued) 









85 & over 
1: 
n=a 
x w P n 
~ 
(l+i In'''l1 
is the m~dyear age for the given cohort of persons; 
is the annual mean ea,mings for a1l persons i'n the category with earnings in an a.ge 
group where the midrJOi'nt is age n; 
is the discount rate; 
is defined as the number of labor force years per person in an age group. 
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PUBLIC SECTOR COSTS 
1. FIRST YEAR 
S6% OF HOSPITAL C6STS AFTER 3 MONTHS 
SO% OF DOCTORS' FEES 
20% OF PATIENTS ON WELFARE 
2. SUBSEQUENT YEARS 
SO% OF HOSPITAL COSTS 
SO% OF DOCTORS' FEES 
20~ OF PATIENTS ON WELFARE 
3. FIRST YEAR 
. . 
SO:(, OF TRANSPLANT OPERATION (SEE TRANSPLANT COST BREAKIDOl~N) 




































































PRIVATE SECTOR COSTS 
1. FIRST YEAR 
CENTER DIALYSIS COST: $17,000 (70%)= 
(SEE CENTER 11IIALYSIS COST BREAKIDOWN) 
HOME IDIALYSIS: $18,450 (30%) = 
AVERAGE 
2. SUBSEQI!lENT YEARS 
CENTER DIALYSIS COST $11,850 x 70% = 
HOME OIALYSIS COST $8,450 x 30% = 
3. FI RST YEAR 
20% OF AVERAGE OPERATION COST PLUS 
OTHER INCI!lRREID COSTS 
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CENTER IDIALYSIS COST BREAKDOWN ($) 
SURGERY FOR CONNECTION 
COUNSELING (50% ASSUMING $15001YEAR) 






SPOUSE OR FAMILY JOB LOSS (iJR REaUCnON 
TP~NSPORTATION COSTS 
DIALYSIS 
3-MONTH INITIAL PERIOID 
!.'EDICARE COVERAGE (80%) 
!~. O. 
3-MOtlTH INITIAL PERIOID 
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SPOUSE OR FI~"'ll 'I .)nr. LOSS 
M.D. 
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TRANSPLANT COST BREAKOOWN 
POST TRANSPLANT 
1ST YEAR YEARS ill 
FROM LIVING PERSON (3!!l% OF mTAl 
X $14.!!l!!l!!l) 
FROM CAIilAV,ER (70% OF TOTAL X $12,80B) 4 
AVERAGE C(1)ST OF OPERATION TO PATI ENT 
(2(1)% OF TOTAL COST) 26!!l!!l 
WORK lOSS 18!!l0 
DONOR ~10RK lOSS 13!!lO C 
MEDICATION ANIil M.Iil. 'S 15!!lO 3500 
DIET CHANGES 200 200 
COUNSELING S!!lO 3!!l0 4 
TUTORING 100 Hl!!l 
DIn SI!JPPlEMENTS 250 
JOB DECREASE (TOO WEAK, CANN(1)1f 
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TRANSITION PROBABILITIES 
SOl!lRCES 
• JAMES E. DALEN ANIil JOSEPH S. ALPERT, "NATURAL HISTORY OF pl!ILMONARY 
EMBOLISM," PROGRESS IN CARIilTOVASCULAR DISEASES, VOL. XVII, NO.4. 
J'ANl!IARY-FEBRUARY. 1975. P. 259-270. 
• AMERICAN HEART ASSOCIATION, "THE WROKINASE pt:JlMONARY EMBOLISM TRIAL: 
A NATIONAL COOPERATIVE STUIilV," MONOGRAPH #39, SWPPLEMENT TO CIRCULATION, 
APRIL , 1973. 
• AMERIC.'IN HEART ASSOCIATION, "UROKIN'ASE-STREPT@KINASE EMBOLISM TRIAL: 
PHASE 2 RESl!ILTS. " JOl!lRNAL OF THE AMERICAN MEDICAL ASSOCIATION, SEPT. 16. 
1974. VOL. 229, NO. 12. 
ASSUMPTIONS 
• THE PROBABILITY OF DEATH FOR THOSE PATIENTS BEING TREATED WITIil 
UROKINASE WILL DECREASE FROM .09 t@ .04. 
• 801', OF PATIENTS WITH A DIAGNOSED pUlLMONARY EMBOLISM WILL BE 
TREATED WITH UROKINASE. 
• A TREATMENT CONSISTING OF A PRECAWnONARY INJECTION OF l!IROKINASE 
WILL BE G,IVEN TO 3lil% OF UNIilIAGNOSEID PATIENTS. THIS INJECTION WOl!lLD 
BE GIVEN BY MEDICS OR EMERGENCY ROOM PERSONNEL AS STANIilARIil PROCEDl!IRE 
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COST A55l:1MPTI0NS F0R PIiIWONARY EMB(!)LISM 
• N(!) EARNrINGS ARE TABULATED, ONLY C(!)STS, BUT LOST EARNINGS ARE CONSIDERED A C(!)ST. 
• EARNINGS (FOR LOST WAGES) WERE OBTAINED FROM THE OEPARTMENT (!)F LABOR. 
• AVERAGE DAilY IN-PATIENT H0SPITAL COSTS F0R 1976 WERE OBTAINED FROM 
THE AMERICAN ItOSPITAL ASS0CIATION • 
• A 10 TO 1 COST REEJUCnON FOR THE PROIDUCn0N 0F UROKINASE WAS ASSUMEI!), 
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COST BREAKgOWN BY TREATMENT STATE 
1. PULM(i)NARY EMBOLI SM -
NONE. BY DEFINITION 
2. flO t:lIIAGNGSIS WITH TREAliMENT 
1 MONTH LOST EARNINGS 
HOSPITAL COSTS 
4 DAYS @ $158.39 
UROKlNASE 
(ROUNDED $1750.) 
3. NO IHAGtlOSIS AND tlO TREATMENT 
1 MONTH LOST EARNINGS 
HOSPITAL COSTS 
'i DAYS @ $158.39 
(ROUNDEB $1700.) 
4. P0ST PULMONARY EMBOLlSM. NO PROPMYLAXlS 
NONE 
5. HEPARIN TREAHNT 
M. D. 
HOSPITAL COST 
5 DAYS INTENSIVE CARE 
@ S4'00/0AY 
9 MEDWI~ CARE @ $158.39 
HEPARIN 
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COST BREAKDOI~N BY TREATMENT STATE (CONTINUED) 
6. UROKINASE AND HEPARIN 
M.!!l. 
HOSPITAL COSTS 
3 DAYS INTENSIVE CARE @$400. 







4 DAYS INTENSIVE CARE @$4I!1D. 





LOST WAGES (2 MONTHS) 
(ROUNIDED $8350.) 
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FILE S F~09JCOST/~ORT/CCOMP . ~rE R r~ , 'JAG ES 
~AT REii C' • 2,0: 
~Rr REA!) * ~ . p' 
~~ r F<EA !) ~ ,; , ... 
o I S P " E lIT E R s!) 1'0 S E F I) F I TE P il " : ~ 'i .; , , 
IN PUT N':l 
FOR L:I TO 4 
Q:l[ Ll 
FORHAT 'TH E HUMBEF OF ITER ii Tr Ol13 IS".F6 , Q 
"=5 
DI~P "EHTER ~r.E AT ONSET" ; 
REM 111PUr 11 
FOR Q2=1 TO 15 
~j R ! T E (2 I 1 1 € f.1 :; ~ j '1 
FO RMQ! ~ T ~EH7 ~Er~T ' : 8 S ~ S ~ .~ F1 0 2 
TE=I ~H (l/~) 
T~=O 
iF Q , = 60 THE ~ 1260 
T9=INT((60-Q'/~) 
LJ R HE (2"Z:l0)(1 
FOPMAT ~THE ~GE AT ~NS ET rS " , ~ G n 
DISP ;'EHTER TPEAT i1 EfiT ~tlJ r·1BEft' r.: 
REM IHPUi Q2 
"AT READ. 5.?Z;U 
IIRlTE (2 . 1150 :"n 
WRITE (2~ 123 {) " 2 [ !) 2.1j,C[ ')1.:1 
FORMAT li THE rRE~rr:E:-IT i~ UnS:Ep. I S" . r j; . ,) 
F'=INT ( Q/ 20)+1 
IF F9 (~ THEN 1390 
F'=4 
"AT IIEAO • t.(F9-1)*4+1;P 
FOR 1 =1 TO 1 0 
rOR .)=1 TO 5 
PC I. J J:P[ I •. J j ·. UC I] 
HE XT J 
HEXT I 
FOR 1=1 TO l C' 
o [ I. 1 1= P[ I. I I 
FOR ,)=2 TO C; 
DC I. J ]=PC I , J J-PC I .J-l] 
II EXT J 
Z=P[Lll 
FOP. J=2 TO 5 oRiGmW tAGH 18 
OF POOlt QUA:Ud\ 
o 
l \ 
~ ,· f 0 0 0 0 0 0 0 
"; 'c" 
I 
i \ \ .~ 
! a 1520 P[I, J l= P [I , Jjl ( I -Z~ 
1530 Z=:+O[I,Jl 
r ,. 1540 HEXT J 1550 FOR .J =6 TO 20 
1 560 P[I.JJ=O 
I IS ? O HE XT J 
t 
1 5 S ~ HOT 1 
15 9 0 PRIN T LINI , ·PRoa"f. ILl TY TAB LE" 
I'~I if, 01) FOR 1 =1 TO 5 lidO FOR J = 1 TO 5 
'r.'!l 16 20 WRITE 
C .. 163 0 l P( I ,oj ] ; 
16 31) FORMAT F 7 . 3 
!6 40 NEXT J 
1 650 PRINT " • 
: i60 /lE XT I 
1(,70 "AT RE AD • 3, ( F9- 1) *4 + 1:0 Hao "AT X= Z ER 
1690 "AT A= l ER 
1 ;' 0 0 "AT S= ZER 
1 7 1 t) "AT E=Z ER 
1 72 0 MAT F= ZER 
1 730 "AT G= ~ ER 
1740 Hs O 
17 5" N=N+l 
~ 
..... 1 76 0 IF H >119 THEN 2280 
~ 
1 77 0 01SP " ITER " N 
1 7 130 IIAT S =ZER 
1790 "AT H= ZER 
1 8 00 '1'=0 
1 al0 Z=1 
1 820 Y=Y +l 
I ~ 1 a 31) Z9=Z 
1 840 A[Y]=A[ Y ] + I 
1 85O 5=C[02 , 1] 
I ~ 18c;,0 IF Y =1 THEN I S8 0 1 8 70 5-C[02 , 2] 
1 S 81) FOR 1=1 TO 11 
I 1890 1 F 5 C 1 ]= 1 TH EH 1"80 . " 1'00 IF RHOQ)P[l, '(] THEN 1 9 90 lHO S=S+RCI.l] 
1920 5[1]=1 
1'30 E[ I ]=E[ I ]+1 
IHO F[I] =F[ 1 1+Y 
1 ~ 50 H[ 1 1= Y 
1-' 1'60 Z=Z+I I l- 1 970 COTO 1990 1 '130 S =S+RCI.2] 
I 1990 HEXT I 
I 2 000 IF Z <3 OR on THEN 21 7 0 
2 010 IF 5[6]=1 THEN 2140 



























































IF Z=3 THEN 20'50 
T2=0 . 35 
IF RHOQ)T2 TH~H 21~O 
Z=Z+1 
5[6]=1 




IF RNOQ}0 . 7 7H<::" 2 17 (1 
CO TO 2150 
5=S+Ct20,21 
)([ Yl=Xt Yl+S 
COTO 21')0 
XC 'I' l=X[ Yl+S 
IF RNOQ)(O[Z , '(l+()[Z<;!,,(] ) "O.'5 THEH 1820 
8[2]=8[21+1 
""='1'+0 . 5 
FOR 1=1 TO "+1 
IF Ht 11=0 THEN 2241) 
C[ I ]=G[ I l+V'-H[ 11 
NEXT I 
IF Ht5]=0 THEN 227Q 
G[51=G['51+0 . '5 
COTO 1750 
51 2 S2=S7=0 
~tolNAL PAGE IS ~'lIOoR QUALlTJJ 
PRINT LINt.' DURAT!ON DEATHS - LOST WAGES 
FOR '1'=1 TO 20 
IF A[Yl=O THE~ 24 0 0 
T7=Y+T8 
D=A[ Yl-A[ '1'+ 11 
IIRITE (2,2350)(Y-l ) ·05+1,"«5,0 , O*'I[17],)([Y]/A[Y] 
FOR"AT FS . O, · - ", F4.0,FI2 . 0,2FI4 . 0 





FOR '1'=1 TO 20 
IF At '1']=0 THEN 2460 





FOR"AT I,'~VE LOST YACES · ,FI2 . 0 
58=1 
IF 5S )= 5 THEN 2520 
58=5S/S 
54=58* C[ Q2, 1 ]+( 5 5-S .. 58 ).Ct Q2, 2l1!5 
WRITE (2,2540)S4,(S7/N9-S4> 
Q o ~ ) 

















































FORPIAT 'TREATI1ENT COSP , FI2 . 0 , 1, "COMPLICATION COST " ,F9 . 0 
WRITE (2.2560)S7iH9 
FORPIAT "AVE TOTAL COST·.FI2 . 0 
S'=S6/N' 
Y=(S6-SS*SS)AO . 5 
WRITE (Z,2600 ) SS+g , u 




53=( 52-S1 *5 I )A O. 5 
N 9 =N-I 
PRINT "PROB OF GETTING NU"BER OF COPIPLICATIOIIS" 
FOR 1=1 TO 7 
P=BCIlIII9 
WRITE (Z,27 1)0)(1-1),P"100,100"«P.(I-P»AO . S) 
FOR"AT F8 . 0,2F10 . 1 
NEXT I 
PRINT 
PRINT 'PROE OF GETTIHG SPECIFIC COMPLICATIOH" 
FOR 1=1 TO 11+1 
P=E[ 11/N9 
WRITE (2.270 ')! , 1 f) I) "' P.I()<)o.«P"'(I-P»AO.S) 
NEXT I 
PRINT 
PRINT "RGE GETTING COMPLICATION" 
FOR 1= 1 TO 11+\ 
5:0 
IF E[ll=O THEH 2860 
s=s*n I lIE[ I ]+Q-2 ::; 
I F I »5 THEil 28(.0 




PRIHT "HUMBER OF YEARS WITH COMPLICATION" 
FOR 1=1 TO 11+1 
S=O 
IF GCI1=0 THEil 2'40 
S=GC I l/E[ I 1*5 






































































































































































































































































































































































































































































































































ANNUAL PER PATIENT COST OF HUMAN INSULIN C 
-, INSULIN & MEDICAL SUPPLY $115 $335 $ 610 
I 
1 2 CLINIC VISITS 96 96 96 
WOR K LOSS (1 DAY) 22 22 22 
DIET CHANGE 200 200 200 
TUTOR ING 100 100 100 









ANNUAL COST PER PATIENT OF ARTIFICIAL 
PANCREAS/FOREIGN INSULIN TREATMENT 
FIRST YEAR 
OPERATION AND DEVICE $12,800 
WORK LOSS 1,800 
MEDICATION (EXCEPT INSULIN) 
AND M.D.'s 1,500 
DIET CHANGES 200 
COUNSELING 500 
TUTORING 100 
DIET SUPPLEMENTS 250 
J08 DECREASE 1,000 
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ANNUAL COST PER PATIENT OF ARTIFICIAL PANCREAS WITH HUMAN INSULIN 
FIRST YEAR FIRST YEAR FIRST YEAR POST YEAR POST YEAR POST YEAR 
HUMAN #1 HUMAN #2 HUMAN #3 HUMAN #1 HUMAN 112 HUMAN #3 
OPERATION AND DEVICE $12,800 $12,800 $12,800 
WORK LOSS 1,800 1,800 1,800 
0 
MEDICATION (EXCEPT INSULIN) 
AND PHYSICIANS 1,500 1,500 1,500 $ 500 $ 500 $ 500 
DIET CHANGES 200 200 200 200 200 
200 
• COUNSELING 
500 500 500 300 300 300 
TUTORING 100 100 100 100 100 
100 
DIET SUPPLEMENTS 250 250 250 
:1. JOB DECREASE 1,000 1,000 1,000 1,000 1,000 1,000 
INSULIN AND ~'EDICAL 
SUPPLIES 115 335 610 115 335 6
10 




" c _ . __ _ 
- - - a " "':'T.", --",,=-c..',-_-< 







MEDICATION & M.D.'S 




JOB DECREASE (UNABLE 
TO CONTINUE OLD SKILL) 
182 









































































COST OF DIABETIC RETINOPATHY 
COST PER PATIENT--DIRECT AND INDIRECT 
$625 FIRST 5-YEAR PERIOD 
$1250 SUBSEQUENT 5-YEAR PERIOD 
SOURCE : DIABETES MELLITUS, NATIONAL INSTITUTES OF HEALTH, [DHEW PUBLICATION 
















COST OF CARDIOVASCULAR COMPLICATIONS 
COST PER PATIENT--DIRECT AND INDIRECT 
$9,940 FIRST 5-YEAR PERIOD 
$11,665 SUBSEQUENT 5-YEAR PERIODS 
• DIRECT COST, COST OF MYOCARDIAL INFARCTION, CHANGES IN THE COSTS OF TREATMENT OF SELECTED ILLNESSES, ANNE A. SCITOVSKY AND NELDA McCALL, HEALTH POLICY PROGRAM, UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, 1975 
• INDIRECT COSTS 37.2 DAYS LOST INCOME FOR INITIAL TREATMENT 









COST OF PERIPHERAL VASCULAR COMPLICATIONS 
COST PER PATIENT--DIRECT AND INDIRECT 
$20,500 FIRST 5-YEAR PERIOD 
$35,000 SUBSEQUENT 5-YEAR PERIOD 
DIRECT COSTS OF FIRST YEAR TREATMENT $3000 (VERY OFTEN AMPUTATIONS) 
INDIRECT COSTS--LOSS OF AVERAGE EARNING CAPACITY 
186 









COST OF NEPHROPATHY TREATMENT 
PER PATIENT COSTS DIRECT AND INDIRECT 
$2,500 FIRST 5-YEAR PERIOD $5,000 SUBSEQUENT 5-YEAR PERIODS 
SOURCES : PREVALENCE OF CHRONIC CONDITIONS OF THE GENITOURINARY, NERVOUS, 
ENDOCRINE, METABOLIC AND BLOOD AND BLOOD-FORMING SYSTEMS AND OF 
OTHER SELECTED CHRONIC CONDITIONS UNITED STATES, 19/3, HEALTH 
RESOURCES ADMINISTRATION, 1977, DHEW PUBLICATIO~ ·~(HRA) 77-1536. 
THE ECONOMIC COST OF ILLNESS REVISITED, BARBARA S. COOPER AND 
DOROTHY P. RICE, 1976, DHEW PUBLICATION NO. (SSA) 76-11703 . 
187 
·' 
.,. -~ !' 
COST OF INSULIN RESISTANCE 
COST PER PATIENT DIRECT AND INDIRECT ( 
$14,433 FIRST 5-YEAR PERIOD 
$12,6B5 SUBSEQUENT 5-YEAR PERIODS 
( 
BREAKDOWN: 
FIRST YEAR POST YEAR 
ADDITIONAL INSULI ~ (BOO UNITS/DAY) $1,460 $1,460 
ADDITIONAL CLINIC VI SITS (4/YEAR) 192 192 • 
NO RMAL DIABETES TREATMENT 533 533 
WORK LOSS 660 352 
HOSPTIAL STAY 1,225 4 
SPECIFIC TREATMENTS 215 
$4, 2B5 $2,537 
SOURCES: MEDICAL ADVISORS C 
JOSLJrI CLINIC 
~ 
188 
